

CURRICULUM VITAE

CONSTANTIN G. IOANNIDES, M.Sc, Ph.D

1. 2010-Present, Owner & Founder, IKAROSBIOS, LLC, Cancer Vaccines, Promotes Education

Prominent Cancer Research and Vaccine Development. Solutions for Scientists & Businesses interested to develop Immunotherapy and Cancer Vaccines

In 2015, my website ikaroscancervaccines.com received more than 7,000 visits from around the world

2. Adjunct Professor of Immunology 2013-2018, Xuzhou, (Suchow), Medical College, Jiangsu, China

3. Inventors advocate 2006-Present, UT System, MD Anderson Cancer Center, ("MDACC"), The University of Texas System, ("UT System"),

A. Accomplishments 2013-2015

1. **Benefactor:** Compelled Galena Biopharma, (GALE, Nasdaq), pay MDACC Invention Utilization Fees.

\$ 2,904,00, Net Grant MDACC invention income from my Grants = \$ 1,021,000.00, (Royalty), + \$1,650,000, (E75, Clinical trial fee) + \$ 233,500, (Royalty-E39), donated by MDACC to Uniformed Services University of Health Sciences, ("USU") and Henry Jackson Foundation ("HJF")

2. 2013. GNBC paid \$ 1,200,000 to HJF, for the trial with AE-37 in MDACC and Hellenic Anticancer Institute, ("HAI"), Athens, Greece. Amount received by MDACC and HAI not disclosed yet.

3. 2014. Won Federal lawsuit 3:13-cv-01745-HA, against Inventors by Mr. Ahn, (President) and Dr. Schwartz, (CEO, GALE), partial successor of Aphera, (licensee of my compounds).

4. 2014. Utility Patent Application, UTSC.PO711, US.D1. First named inventor, Controlled modulation of amino acid side length of peptide antigens.

B. Current Activities

5. To recover UT System royalties and stock lost by Breach of Contract & Qui-Tam

6. To correct Qui-Tam/Misappropriation of US Patent '256 from UT System by HJF

7. To persuade HJF to correct Clinical Trial Protocols to include IL-12 and genetic testing.

8. To persuade MDACC Administrators to report to NIH and use royalties received from my inventions for cancer research and education

9. 2015 Member Editorial Board: SOJ Gynecology, Obstetrics and Women's Health

10. 2011-2013, Advisor ERASMUS Program, Greece, (Pro-Bono)

11. 2010-2013, Member, Center for Minorities Health, National Cancer Institute (Pro-Bono)

7. 1992-2014 Federally Funded inventor, Independent Contractor, Principal Creator, Inventors Advocate Funds \$ 4,403,555.10, (not adjusted for inflation),

My compounds E75 and E39 induced the best disease free survival, (DFS), for any experimental cancer vaccine. My co-inventors are

1. E75: Bryan Fisk: 75.00% DFS, 3 years HER-2¹⁺²⁺ patients Stage II-III, breast cancer Tumors express HER-2 protein, 10-100 more than normal cells. Phase III, complete, results pending, July 2016.

2. E39: Maria Ioannides: 88.00 % DFS, 13 months, Stage III ovarian cancer. Phase II ongoing

3. E75 + Herceptin: George Peoples: DFS, 3 years, (100 %) HER-2³⁺ patients, (tumors express HER-2 > 1000 than normal, Phase II completed

4. AE-37 A Phase II trial which used AE-37, without IL-12 was inconclusive or failed

EDUCATION

1. Ph.D, 1982, University of Athens, Athens, Greece, Biochemistry, Mentor Professor Dr. Constantine Sekeris.
2. M.Sc, 1972, University of Bucharest, School of Chemistry, Bucharest, Romania, Biochemistry, Mentor Associate Professor, Dr. Ion F. Dumitru.

POSTDOCTORAL TRAINING

1. "Visiting" Scientist, Department of Immunology, U.T.M. D. Anderson Cancer Center, Anderson, Houston, Texas 77030, ("MD. Anderson"), Mentor: Dr. Chris D. Platsoucas, 9/1985 - 9/1987.
"Visiting Scientist" J-1 Visa is Post-Doctoral Fellow, >3 years post PhD experience from Foreign Country.
2. "Visiting" Scientist, Department of Microbiology, Mt. Sinai School of Medicine, New York, 10029, Mentor: Dr. Constantin A. Bona, 4/1985 - 9/1985.
3. Assistant Professor of Research, Department of Immunology, Hellenic Anticancer Institute, Athens, Greece, Mentor: Dr. Michael Papamichail, 9/1981 - 3/1985. **Title: 3rd Researcher salary & Rank Asst Professor).**

PREVIOUS ACADEMIC APPOINTMENTS

1. Chemist I and Chemist II, Department of Bacterial Biochemistry, Cantacuzino Institute for Immunology, Microbiology and Vaccines, Bucharest, Romania. ("Cantacuzino Institute"), 1972 - 1975.
2. Assistant Director, Culture Media Laboratory, Cantacuzino Institute, 1972-1975.
3. Chemist-III, (*highest rank*) Department of Virology, Cantacuzino Institute, 1975 - 1978
4. Research Assistant, Department of Immunology, Hellenic Anticancer Institute, 10/78 - 8/81,
5. Assistant Immunologist and Assistant Professor of Immunology, (Gynecology), Department of Gynecologic Oncology, ("Gyn-Oncol"), MDAnderson, 77030, 10/87 - 8/93.
7. Associate Immunologist and Associate Professor of Immunology Gyn-Oncol, MD Anderson, 1993 - 1999.
8. Assistant Director, Immunology and Molecular Biology, Gyn-Oncol, MD Anderson, 1988 - 1995.
9. Professor of Immunology, Gyn-Oncol, MD Anderson, 9/2000-8/31/2008.
10. Professor, Experimental Therapeutics, MD Anderson, 9/2008-1/2010.
11. Director, Immunology & Vaccine Research Laboratory, Gyn-Oncol. MD Anderson 1998 - 2010. Saved > \$ 87,000.00 in administrative costs to MD Anderson, 5/20/2005-8/31/2008.
12. Member, University of Texas Health Science Center, Graduate School of Biomedical Sciences, Houston
13. Affiliated Member, The Center of Minority Health.
14. Terminated. Leave as Mother Only Caretaker, 2/1/2010-5/10/2011-deceased
15. Founder LLC

HONORS AND AWARDS

1. Commendation, President MD Anderson for donation, 2009.
2. President of MDACC Silver Club Member, 2006-2007, Donated my External Fees to MDACC.
3. Commendation, Dean Kurume University, for training of Satoko Matsueda. 2007, (Japan)
4. Commendation, Scientific Chairman Prof. Dr. Eng. Zoltan Puklus, for critical advice to MULTI-FORUM'07, Jean Monet, 2007. (Hungary)
5. Invited Foreign Member, European Society for Cancer Immunology and Immunotherapy, 2006 (Honor)
6. Invited Founding Member, The Robert Good Immunological Society, 2005 (Honor)
7. Invited Foreign Member, Japanese Society of Gynecologists, 2005. (Honor)
8. Commendation, Breast Clinical Care Program, Walter Reed Medical Center, Washington, DC, 2004.
9. Invited Fellow Member, Society for Biological Therapy, (2002 - 2009), (Honor)
10. Commendation, Breast Clinical Care Program, Walter Reed Army Medical Center, Washington, 2003.
11. Employee Service Awards 15 and 20 years/Diplomas, 2000, 2005.
12. Dean's Excellence Award (GSBS), 1999, 1996, 1995, 1994,
13. Dean's Teaching Award (GSBS), 1999.
14. Fulbright Scholar, 1985.

EDITOR, SCIENTIFIC DIRECTOR OF EDITIONS, ORGANIZER OF SCIENTIFIC MEETINGS

Editor: 1. The Open Vaccine Journal 2007-2010. 2. Lymphokine and Cytokine Research 1995 – 2008, 3. Anticancer Research, 1993 – 2010, 4. In Vivo, 1994-2010 5. Journal of Cancer Epidemiology.

Guest Editor: 1. Breast Diseases, 1994 – 2001, 2. International Reviews of Immunology, 1990

2. Edition: Proceedings International Conference on Interdisciplinary Education: ICIE 2005, 2006, 2007

3. Edition: Abstracts of International Conference: Interdisciplinary Education, ICIE 2005, ICIE 2006.

4. Scientific Advisor and Organizer, *JEAN MONET Multidisciplinary Higher Education and Research International Forum, USA- Europe: Integration of women from Africa, Middle East and Former Eastern Soviet Union.* The most prestigious European integration program, 2006, 2007.

5. Tuning Counsellor, SOCRATES –ERASMUS Program. Guidelines and methods for postgraduate education in multidisciplinary fields. 2006.

6. Member, Organizing Committee. 9th International Meeting, Anticancer Research, Kos, Greece, 2008.

7. Member, Organizing Committee. 8th International Meeting, Anticancer Research, Crete, Greece, 2006.

8. Scientific Advisor and Assessor of International Steering Committee the 3rd International Conference: Interdisciplinary Education ICIE '07 and Multi-Forum '07, Athens, Greece, 2007

9. Member, Organizing Committee. 7th International Meeting of Anticancer Research, Crete, Greece, 2004.

10. Member, Organizing Committee, Symposium, Fundamental Cancer Research, MD Anderson, 2003.

11. Session Co-Chair, Symposium, Intercultural Cancer Council, 7th Biennial Symposium, Washington, 2000.

12. Organizer, Symposium, Tumor Infiltrating Lymphocytes, Annual Meeting, AACR, Florida, 1993.

13. Member, Organizing Committee, 4th International Meeting Anticancer Research, Organizer, Symposium Immunotherapy of Cancer, Crete, Greece, 10/92.

14. Member, Organizing Committee, 2nd International FASEB Summer School in Immunology, Greece, 1984.

15. Member, Organizing Committee, 1st International FASEB Summer School in Immunology, Greece, 1982.

EXTERNAL SCIENTIFIC ADVISORY BOARDS

1. Windber Cancer Institute, Johnstown, PA, 2001 – 2006.

2. DOD Clinical Breast Cancer Program, USUHS, *Washington, DC, 2001 – 2006.*

3. NCI-Gynecologic Cancer Center, Comprehensive Center for Minorities Health, *2004-2005.*

4. Gynecologic Cancer Center, USUHS, *Columbus, Ohio, 2005.*

5. BN-Immunotherapeutics, Mountain View, CA, 2006-2007.

6. Supported Immunology Laboratory of the Clinical Breast Cancer Program of the Walter Reed Medical Center, Washington DC, 2001-2002 when Dr. Peoples was in Afghanistan.

7. Healthcare Council of Gershon-Lehrman, advisory to Morgan-Stanley, 2006-2007.

8. APTERA, 2007- 2009

9. Imuc, Immuno Cellular Therapies, 2009-2012.

Consultant

1. TEVA Pharmaceuticals, Israel, 2002

2. PO1. Immune Effectors in the Tumor Environment, Pittsburgh Cancer Institute, 1998 – 2002

3. Argonex Corporation, Charlottesville, VA, 1997-2002

4. Searle Pharmaceuticals, St. Louis, 1996 – 1997.

5. Department of Science and Technology of Greece, Development of Polyclonal Antibodies, Athens, 4/84

IMPACT OF MY DISCOVERIES IN CANCER TREATMENT The highest achievement of a Cancer Immunologist.

1. New scientific theory about presentation of immunogenic Human Cancer Antigens.

2. I discovered highly-specific, low cost, antigens for cancer vaccines. **My tumor antigens prevent metastases.**

3. Economic Return of my discoveries: Investigators, which perform Clinical Trials, received very high amounts of funds, created high-quality new jobs and trained young people.

4. Support for Basic Human Rights. 25 % of women patients, live without metastases for 5 years.

SUPPORT FOR CANCER VACCINE TRIALS, LICENSING AND DEVELOPMENT

1. *Study Co-Chairman*, Protocol: ID 96-71. Phase Ib trial of HER-2/neu peptide (E75) vaccine in patients with breast and ovarian cancer: *Study Chairman:* James L. Murray, M.D., 1997 – 2001.

2. *Collaborator*: Phase I vaccine trial of a HER-2/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers: *Study Chairman*: James L. Murray, M.D. 1999-2001.
3. *Co-Investigator*. WRAMC. WU. #00-2005. Phase Ib Trial of her-2/neu peptide (E75) vaccine in breast cancer patients at risk for recurrence after surgical and medical therapies. *Study Chairman*: Lt Colonel, George E. Peoples, MD, USAMC, Co-Chairman, Colonel Craig Shriver, MD, USAMC. (2001-2008)
4. *Immune monitoring of 14 breast cancer patients treated, at MDACC with E75+GM-CSF* by Dr. James Murray. I developed methodology for detection of immune responses and performed all monitoring in my laboratory at no cost to MDACC. 1998-2002.
5. Principal Inventor, Inventors representative, manager in negotiations with *Advanced Peptide Therapeutics*, for commercialization of my technology. 2005
6. Principal Inventor, Inventors representative, negotiator with *Emergent Technology*, 2007
7. Principal Investigator, Inventors representative, negotiator with *Immune Cellular Therapies, Ltd* for licensing of my technology. 2009.

PATENTED FEDERALY FUNDED INVENTIONS.

1. USP: 10/507,009, ('618), 8/12/2014. Controlled modulation of immunogenicity by amino acid side length. *Ioannides CG, O' Brian CA, Campbell M, Peoples GE*. Assignee Board. MDA01-049; UTSC.P0711US.D1; U.S. Application No. 14/445,776
2. USP 8,258,261, 9/4/2012. Induction of tumor immunity by variants of folate binding protein *Ioannides CG, Peoples, Jr.; George E, Kathleen Ann (Newton, MA)* Assignee HJF. No. 14/339,797 (Continuation of U.S. Patent Application No. 13/556,876) Title: Induction of Tumor Immunity by Variants of Folate Binding Protein.
3. USP 7,547,759, 6/16/2009. Cancer immunity by variants of folate binding protein. *Ioannides CG and Peoples, GE* Assignee UT System Board of Regents (Board)
4. USP 7,348,153, 3/25/2008. Novel melanoma peptide-vaccines derived from the high molecular weight proteoglycan antigen. *Ferrone S, Ioannides CG, Kawano, K, Murray, JL*. Assignee Board.
5. USP' 6,514,942, 2/4/2003. Methods and compositions for stimulating T-lymphocytes. *Ioannides CG, Bryan Fisk B and Ioannides, MG*. Assignee Board
6. USP 5,434,076 7,1995. Human ovarian tumor-specific monoclonal antibodies. *R.S. Freedman, C. G. Ioannides, R. Patenia, and B. Tomasovic*. Assignee Board.

PATENT APPLICATIONS TO BE REVIVED

7. USPA 12,529,759 Submitted 3/09/2009. Cancer therapy by Notch and Numb tumor antigens. *Ioannides CG, Matsueda S, Mine T, Li Yufeng*. Assignee: Board.
8. USPA 12,262,402 Submitted 01/05/2010. Mosaic helper peptides. *Ioannides CG, Murray JL, Peoples GE, Efferson C, Kawano K, Tsuda N, Matsueda S, Li Yufeng*. Assignee: Board

INVENTIONS CLOSED, (INACTIVE), DUE TO FIRING, 2010 CAN BE REVIVED.

9. Cancer Therapy by designed micro-RNA. *Tsuda N, Kawano K, Chang DZ, Ioannides CG*. 2007.
10. Priming of Th1 help and modulation by cytokines with opposed effects for cancer vaccination. *Murray, JL, Kuerer H, O'Brian CA. and Ioannides, CG*, 2001.
11. Short pyknons in human RNA as anticancer agents. *Li Y, Ioannides, CG*. MDACC 09-094. 2009.

EXTERNAL FUNDS: (1992-2014):

\$ 4,403,555.10, not adjusted for inflation or \$220,000.00 a year, [(\$ 1,205,903.10 + 225,420 + 811,000.00 + 1,745.975.00 + 415,257.00)]

Grant Income: 2006-2014: \$ 1,205,903.10

1. Grant of License E75, Principal Inventor & Creator, 2014	100,000.00
2. Grant of License E75, (I +MDACC),2011-2013	573,000.00
3. Grant of License,FBP,2012-2014, (DOD and I 50% of Total)	75,000.00
4. Grant of License ,FBP,2011, (MDACC, HJF and I (50% of Total)	125,500.00
5. Grants of License IMUC,Numb , (stock not included),2007-2009	55,000.00
6. Grant of License: E75, 2006-2010	377,403.10

Grants of Assistance, National and international, 2006-2010:225,420

7. Sponsor,Fellowships Japan for Research in my Laboratory: 2006-2007.	125,000.00
a. Satoko Matsueda, 11/12/2005,Graduate student, Kanazawa Foundation	5,000.00
b. Satoshi Ishiyama, MD. 11/1/2005 Assistant Professor, Mitsukoshi Foundation,	50,000.00
c. Takashi Mine. MD, PhD. 6/14/2006,Senior Assistant Professor, Kurume University	70,000.00
8. NCI Ramesh Grant of Assistance 2007-2010, (Investigator)	34,250.00
9. EU Erasmus and Jean Monet Grants,2006-2009	42,170.00
10. Toppfer Philanthropic Fund,2006	24,000.00

External Funds, 2000-2005 - 811,000.00

10. Grant Antigen-Express. 9/1/03-6/30/2009. J. L. Murray (PI). Ioannides. Direct	137,000.00
11. Bristol Myers,2002, <i>Principal Investigator, PI</i>	36,000.00
12. Melanoma SPORE,P50-CA093459-01A1,2004	65,000.00
13. Research Grant,Keck Foundation. 2002	50,000.00
14. Research Grant: R01-DAMD-17-01-1-0299. U.S. Army 2001	433,000.00
15. Grant Antigen Express Corporation, 2000	40,000.00
16. Fellowship, Bjum Kyum Ko, Associate Professor of Surgery, Ulsan, Korea	50,000.00

External Funds,1992-1999 - \$ 1,745,975.00

17. Research Grant,RO1-DAMD 17-97-I-17098	430,000.00
18. Research Grant. Corixa Corporation 1995	15,700.00
19. License Grant Methods Corixa 1997	20,000.00
20. License Grant,Argonex Corporation, 1997	47,775.00
21. Phase Ib Clinical Trial E75. Corixa(James L. Murray PI) Study Co-Chairman, 1997	70,000.00
22. Research Grant, RO1-DAMD-17-94-J4313 US Army,1994	718,000.00
23. Research Grant, PI,Women's Fund, 1998.	9,500.00
24. NIH Doctoral Fellowship: (Agapito Castilleja,) Sponsor, 1997	45,000.00
25. ACS Fellowship M. Chen, M.D., Sponsor,1995	5,000.00
26. Nellie Connally Breast Cancer Research Fund,1995	25,000.00
27. Research Grant NCI, RO1-CA-57293,1992	360,000.00

External Funds,1985-1991, Historical Value, (alone \$ 102,900) 415,257.00

28. Research Grant: NIH, RR-05511,1991	19,500.00
29. University Cancer Foundation,1991	50,000.00
30. Research Grant: Texas Technology, (PI,Freedman,RS), 1989 Co-PI,Money Split	233,257.00
31. Research Grant: Sandoz,(PI, Freedman,RS) <i>Co-Investigator</i> , 1988-1991,	79,100.00
32. UT System Philanthropists for " Visitors" 1985	25,000.00
33. Research Grant Fulbright Foundation,1985,	8,400.00

COLLEGIAL CO-INVESTIGATOR

34. Cancer Biology Training Grant, NIH (Elizabeth A. Grimm, PI), 1998,	400,000.00
--	------------

35. Breast Cancer Training Grant, DOD, (Mien-Chie Hung, PI), 1999,	400,000.00
36. Bio-immunotherapy Training T32-CA72321, (Gabriel Lopez, PI), 1998,	1,800,000.00
37. Spore Grant Lung Cancer, P50: CA 70907, Jack Roth, PI, 1996,	4,000,000.00
38. Breast Cancer Integration, R21-CA66225, (James D. Cox, PI), 1995	350,000.00
39. Training Grant Gynecology T32-A09623 (J. Taylor Wharton, PI), 1991	300,000.00
40. Active specific immunotherapy CA-29592, (Barry J. Kahan, PI), 1987	1,080,000.00
41. Research Grant: R01, (M. Papamichail, PI), Greece, 1985,	25,000.00
42. Research Grant: R01, (M. Papamichail, PI), Greece, 1984,	27,000.00
43. Research Grant R01, Greece, PI, 1984	35,000.00

PUBLICATIONS: 140

Teaching aids: 3

Peer-reviewed articles in book chapters = 12

Commentaries: 14

Citations research, 1987-2015 > 3900

ARTICLES IN PEER-REVIEWED JOURNALS

Hellenic Anticancer Institute, Athens, Greece, 1979-1986

1. Papamichail, M., **Ioannides, C.G.**, Tsawdaroglou, N., and Sekeris, C.E. Translocation of glucocorticoid receptors in PHA-stimulated lymphocytes in the absence of the steroid. *Exp. Cell Res.*, 133:461-465, 1981.
2. Lambris, J., Papamichail, M., **Ioannides, C.G.**, and Dimitracopoulos, G. Activation of the alternative pathway of human complement by the extracellular slime glycoprotein of *Pseudomonas aeruginosa*. *J. Infect. Dis.* 145:78-82, 1982.
3. Papamichail, M., **Ioannides, C.G.**, Agnantis, N., Garras, J., Tsawdaroglou, N., Leventakou, A., and Sekeris, C.E. Immunocytochemical detection of glucocorticoid receptors in lymphocytes and breast tumor cells. *NATO Adv. Study Inst. Ser.* 157:347-356, 1982.
4. **Ioannides, C.G.**, Papamichail, M., Agnantis, N., Garras, J., Tsawdaroglou, N., and Sekeris, C.E. Glucocorticoid receptors in breast cancer. Detection by immunochemical and biochemical methods. *Int. J. Cancer* 29:147-152, 1982.
5. **Ioannides, C.G.**, Tsawdaroglou, N., Papamichail, M., and Sekeris, C.E. Biological functions of glucocorticoid receptors in lymphocytes. *Progr. Clin. Biol. Res.* 103:181-191, 1982.
6. Tsiapalis, C.M., **Ioannides, C.G.**, Trangas, T., Courtis, N., Pangalis, G.A., Cosmides, H.V., and Papamichail, M. Poly(A) polymerase levels in lymphoid cells from acute and chronic lymphocytic leukemia. *NATO Adv. Study Inst. Series* 157:233-241, 1982.
7. Papamichail, M., Trangas, T., Courtis, N., **Ioannides, C.G.**, Cosmidou, H., Pangalis, G.A., Tsiapalis, C.M. Poly(A)-polymerase levels in leukemia. *Haemat. Bluttransf.* 28:28-29, 1983.
8. Trangas, T., Courtis, N., Cosmides, H.V., Pangalis, G.A., **Ioannides, C.G.**, Papamichail, M., and Tsiapalis, C.M. Poly(A) polymerase and poly(A) nuclease levels in leukemias. *Cancer Res.* 44:3691-3697, 1984.
9. Baxevanis, C., **Ioannides, C.G.**, and Papamichail, M. The role of self-Ia antigens in the murine MLR. *European J. Immunol.* 16:361-365, 1986.
10. Petraki, H., **Ioannides, C.G.**, Filli, S., and Papamichail, M. Loss and reappearance of transferrin receptors in human leukemic cell lines during differentiation. *Exp. Cell Biol.* 54:80-88, 1986.
11. Baxevanis, C., **Ioannides, C.G.**, Reclus, G., and Papamichail, M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. *European J. Immunol.* 16:1013-1016, 1986.

M. D. Anderson Cancer Center

12. Meyer, R., **Ioannides, C.G.**, Moran, T., Johansson, B., and Bona, C.A. Effect of syngeneic anti-idiotypic antibody on influenza virus neuraminidase antibody responses. *Viral Immunol.* 1:121-134, 1987.
13. **Ioannides, C.G.**, Itoh, K., Fox, F.E., Pahwa, R., Good, R.A., and Platsoucas, C.D. Identification of a second T cell antigen receptor in human and mouse by an antipeptide g-chain specific monoclonal antibody. *Proc. Natl. Acad. Sci. USA*, 84:4244-4248, 1987.

14. **Ioannides, C.G.**, Platsoucas, C.D., Bowen, J.M., Wharton, J.T., and Freedman, R.S. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate therapy. *Anticancer Res.* 9:81-86, 1989.
15. Seki H., Nanno, N., Cheng, P.F., Itoh, K., **Ioannides, C.G.**, and Platsoucas, C.D. Disulphide and non-disulphide linked gd T-cell antigen receptors (TCR) expressed on T-cell clones from normal donors. *Proc. Natl. Acad. Sci. USA* 86:2326-2330, 1989.
16. **Ioannides C.G.**, Freedman, R.S., and Platsoucas, C.D. OKT4 monoclonal antibody induced activation of an autoreactive T cell clone from a patient with ovarian carcinoma. *Cell. Immunol.* 123:244-252, 1989.
17. Nanno M., Seki, H., Bao, Y., **Ioannides, C.G.**, Morkowski, J., and Platsoucas, C.D. Development of a monoclonal antibody specific for the g-chain of the T cell antigen receptor using an open reading frame expression vector. *Hybridoma* 8:227-291, 1989.
18. **Ioannides C.G.**, Platsoucas, C.D., O'Brian, C.A., Patenia, R., Bowen, J.M., Wharton, J.T., and Freedman, R.S. Viral oncolysates in cancer treatment: Immunological mechanisms of action. *Anticancer Res.* 9:535-544, 1989.
19. Platsoucas, C.D., Fox, F.E., Oleszak, E., Fong, K., Nanno, M., **Ioannides, C.G.**, and Trotta, P.P. Regulation of natural killer cytotoxicity of recombinant α - interferons. Augmentation by IFN- α 7, an interferon similar to IFN- α J. *Anticancer Res.* 9:849-858, 1989.
20. **Ioannides, C.G.**, Platsoucas, C.D., Patenia, R., Kim, Y-P, Bowen, J.M., Morris, M., Edwards, C.L., Wharton, J.T., and Freedman, R.S. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. *Anticancer Res.* 10:645-654, 1990.
21. **Ioannides C.G.**, Platsoucas, C.D., and Freedman, R.S. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. *In Vivo* 4:17-24, 1990.
22. O'Brian C.A., **Ioannides, C.G.**, Ward, N.E., and Liskamp, R.M. Inhibition of protein kinase C and calmodulin by the diastereomers Cis- and Trans- tamoxifen. *Biopolymers* 29:97-104, 1990.
23. **Ioannides, C.G.**, Freedman, R.S., Lipskamp, R., Ward, N.E., and O'Brian, C.A. Inhibition of IL-2R induction and IL-2 production by a novel PKC peptide inhibitor N-m-KRTLRL. *Cell. Immunol.* 131:242-252, 1990
24. Morkowski, J.J., Nanno, M., Chen, P-F, Itoh, K., **Ioannides, C.G.**, Kruziel, E., Becker, F.F., and Platsoucas, C.D. IL-2 dependent murine T cell lines and clones expressing gd T cell antigen receptors. I. Functional and biochemical characterization. *Scandinavian J. Immunol.* 34:779-794, 1991.
25. **Ioannides C.G.**, Platsoucas, C.D., Rashed, S., Wharton, J.T., Edwards, C. L., and Freedman, R.S. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. *Cancer Res.* 51:4257-4265, 1991.
26. **Ioannides C.G.**, Freedman, R.S., Rashed, S., Platsoucas, C.D., and Kim, Y-P. Cytotoxic T cell clones isolated from ovarian tumor infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. *J. Immunol.* 146:1700-1707, 1991.
27. Freedman, R.S., **Ioannides, C.G.**, Tomasovic, B., Patenia, R., Zhang, H-Z, Liang, J., and Edwards, C.L. Development of a cell surface reacting human monoclonal antibody agent in ovarian carcinoma. *Hybridoma* 10:21-33, 1991.
28. **Ioannides, C.G.**, Freedman, R.S., Patenia, R., Bowen, J.M., Ward, N., and O'Brian, C.A. Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. *In Vivo* 5:1-6, 1991.
29. **Ioannides C.G.**, Rashed, S., Fisk, B., Fan, D, Itoh, K., and Freedman, R.S. Lymphocytes infiltrating ovarian malignant ascites: Modulation of IL-2 induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF- α . *Lymph. Cyt. Res.* 10:307-315, 1991.
30. **Ioannides, C.G.**, and Freedman, R.S. Selective usage of TCR V β in tumor specific CTL lines isolated from ovarian tumor associated lymphocytes. *Anticancer Res.* 11:1919-1926, 1991.
31. **Ioannides, C. G.**, and Freedman, R. S. T cell responses to ovarian tumor vaccines. *Intl. Rev. Immunol.* 7: 349-364, 1991.
32. Fan, D., Clyde, R. K, **Ioannides, C. G.**, and O'Brian, C. A. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer. *In Vivo* 5: 571-578, 1991.
33. Nanno M., Seki, H., Mathioudakis, G., Suzuki, S., Itoh, K., Chen, P-F, **Ioannides, C. G.**, Suzuki, R., and Platsoucas, C.D. gd-antigen receptors on T cells derived from tumor infiltrating lymphocytes from patients with solid tumors. *European J. Immunol.* 22:679-687, 1992.

34. **Ioannides C. G.**, Fisk, B., Tomasovic, B., Pandita, R., Aggarwall, B. B., and Freedman, R. S. Induction of IL-2 receptor by TNF- α on cultured ovarian tumor associated lymphocytes. *Cancer Immunol. Immunother.* 35:83-91, 1992.
35. Nanno, M., Seki, H., **Ioannides, C.G.**, Itoh, K., Day, N.K., Good, R.A., and Platsoucas, C.D. Disulfide-linked and non-disulfide-linked g-d T-cell antigen receptors: Differential expression by T cells derived from normal donors and patients with primary immunodeficiency disorders. *Anticancer Res.* 12:1069-1079, 1992.
36. **Ioannides, C. G.**, Ioannides, M. G., and O'Brian, C. A. T cell recognition of oncogene products. A new strategy for immunotherapy. *Mol. Carcinog.* 6:77-81, 1992.
37. Freedman, R. S., **Ioannides, C. G.**, Mathioudakis, G., and Platsoucas, C. D. Novel immunologic strategies for the treatment of ovarian carcinoma based on cell surface recognition. *Am. J. Obst. Gyn.* 167:1470-1478, 1992.
38. **Ioannides, C. G.** and Whiteside, T. J. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer. *Clin. Immunol. Immunopathol.* 63:91-106, 1993.
39. **Ioannides, C. G.**, Fisk, B., Pollack, M., Frazier, M. L., Wharton, J.T., and Freedman, R. S. Cytotoxic T cell clones isolated from ovarian tumor infiltrating lymphocytes recognize common determinants on allogeneic tumors. Implication for identification of TIL defined Ag on tumors. *Scandinavian J. Immunol.* 37:413-424, 1993.
40. Mayer, R., Han, A., Fisk, B., and **Ioannides C.G.** Common TCR-b chain rearrangements in short-term cultured lymphocytes infiltrating ovarian tumors. *Intl. J. Oncol.* 2:851-856, 1993.
41. **Ioannides, C.G.**, Fisk, B., Jerome, K., Irimura, T., Wharton, J.T., and Finn, O.J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. *J. Immunol.* 151:3693-3703, 1993.
42. **Ioannides, C. G.**, Fisk, B., Fan, D., Biddison, W. A., Wharton, J.T., and O'Brian, C.A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. *Cell. Immunol.* 151:225-234, 1993.
43. Fisk, B., Flytzanes, C.N., Tucker, S., and **Ioannides, C.G.** Dissimilar TCR Vb frequencies in TIL infiltrating primary, secondary and ascitic ovarian tumors. *Intl. J. Oncol.* 3:1111-1120, 1993.
44. O'Brian, C. A., Ward, N. E. **Ioannides, C. G.** Altered signal transduction in carcinogenesis. *Adv. Cell. Mol. Biol.* 7:61-88, 1993.
45. Freedman, R.S., Bowen, J.M., Delcos, L., Edwards, C.L., Wallace, S., Atkinson, E.N., **Ioannides, C.G.**, Kasi, L.P., Scott, W., and Patenia, R. Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate. A Pilot study. *Intl. J. Gyn. Cancer.* 4:101-110, 1994.
46. Fisk B., **Ioannides, C.G.**, Aggarwal, S., Wharton, J.T., O'Brian, C.A., Restifo, N and Glisson, B. Differential expression and inducibility of TAP1 and TAP2 genes in drug resistant and sensitive tumor cell lines. *Lymph. Cytok. Res.* 13:125-131, 1994.
47. Fisk, B., Chesak, B., Ioannides, M.G., Wharton, J.T. and **Ioannides, C.G.** Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. *Intl. J. Oncol.* 5:51-63, 1994.
48. Fisk, B., Chessak, B., Pollack, M., Wharton, J.T. and **Ioannides, C.G.** Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. *Cell. Immunol.* 157, 412-427, 1994.
49. Fisk, B., Flytzanis, C.N., Pollack, M., Wharton, J.T., and **Ioannides, C.G.** Characterization of T cell receptor V b repertoire in ovarian tumor reactive CD3⁺CD8⁺CD4⁻ CTL lines. *Scandinavian J. Immunol.* 40, 591-600, 1994.
50. Fisk, B., Blevins, T.L., Wharton, J.T. and **Ioannides, C.G.** Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor specific CTL lines. *J. Exp. Med.* 181: 2109-2117, 1995.
51. Fisk, B., Savary, C., Hudson, J.M., O'Brian, C.A., Murray, J. L., Wharton, J.T. and **Ioannides, C.G.** Changes in a HER-2 peptide up-regulating HLA-A2 expression affect both conformational epitopes and CTL recognition. Implications for optimization of antigen Presentation and tumor specific CTL induction. *J. Immunother.* 18, 197-209, 1996.
52. Fisk, B., DaGue, B., Seifert, W., Kudelka, A., Murray, J.L., Wharton, J.T., and **Ioannides, C.G.** Mass-spectrometric analysis of naturally processed peptides recognized by ovarian tumor associated CD8⁺ CTL. *Intl. J. Oncol.* 10:159-169, 1997.

53. Fisk B., Anderson, B. W., Gravitt, K., O'Brian, C. A., Kudelka, A. P., Murray, J. L., Wharton, J. T. and **Ioannides, C. G.** Identification of naturally processed human ovarian peptides recognized by tumor associated CD8⁺ CTL. *Cancer Res.* 51:87-93, 1997.
54. Fisk B., Hudson, J. M., Kavanagh, J., Murray, J. L., Wharton, J. T., **Ioannides, C. G.**, and Kudelka, A. P. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patient to HER-2 peptides. *Anticancer Res.* 17:169-179, 1997.
55. Hudson, J.M., Castilleja, A., Murray, J.L., Honda, T., Kudelka, A., Singletary, A.E., Wharton, J.T., and **Ioannides, C.G.** Growth and antigen recognition by tumor infiltrating lymphocytes from human breast cancer. *J. Interf. Cytok. Res.* 18:529-536, 1998.
56. Peoples, G.E., Anderson, B.W., Fisk, B., Kudelka, A.P., Wharton, J.T., and **Ioannides, C.G.** Ovarian cancer-associated lymphocytes recognize folate binding protein (FBP) peptides. *Ann. Surg. Oncol.* 5(8):743-750, 1998.
57. Pride, M.W., Shuey, S., Grillo-Lopez, A., Braslawsky, G., Ross, M., Legha, S.S., Eton, O., Buzaid, A., **Ioannides, C.G.**, and Murray, J.L. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic mabs (MELIMMUNE) which mimic the high molecular weight proteoglycan antigen. *Clin. Cancer Res.* 4:2363-2370, 1998.
58. Babcock, B., Anderson, B.W., Papayannopoulos, I., Castilleja, A., Murray, J.L., Stifani, S., Kudelka, A.P., Wharton, J.T., and **Ioannides, C.G.** Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino-enhancer of split protein of the Notch complex. *Mol. Immunol.* 35:1121-1133, 1998.
59. Fisk, B., and **Ioannides, C.G.** Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug-sensitivity. *Cancer Res.* 58:4970-4973, 1998.
60. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients *Clin Cancer Res.* 1998 Aug;4(8):2015-24.
61. Stewart, J. R., Ward, N. E., **Ioannides, C. G.**, and O'Brian, C. A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. *Biochemistry*, 38:13244-13251, 1999.
62. Anderson, L. D. Jr., Hudson, J. M., Savary, C. A., Fisk, B., Gershenson, D. M., and **Ioannides, C.G.** HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells. *Cancer Immunol Immunotherapy*, 48(7):401-410, 1999.
63. Peoples, G.E., Anderson, B.W., Lee, T. V., Murray, J.L., Kudelka, A.P., Eberlein, T.J., Wharton, J.T., and **Ioannides, C.G.** Vaccine implications of folate binding protein in epithelial cancers. *Clin. Cancer Res.*, 5:4214-4223,
64. Kim, D., Lee, T. V., Castilleja, A., Anderson, B. W., Kudelka, A. P., Murray, J. L. Sittisomwong, T., Wharton, J. T., Kim, J., **Ioannides, C. G.** Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. *Anticancer Res*, 18:2907-2916, 1999.
65. Murray, J.L., Hudson, J.M., Ross, M.I., Zhang, H., and **Ioannides, C.G.** Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression. *J. Immunotherapy*. 23, 28-35, 2000
66. Lee, T.V., Castilleja, A., Peoples, G.E., Kim, D-K, Murray, J.L., Gershenson, D. M., and **Ioannides, C. G.**, Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides, *J. Interf. Cytokine Res.*, 20,391-401, 2000.
67. Yen, N., **Ioannides, C. G.**, Xu, K., Swisher, S. G., Lawrence, D. D., Kemp, B. L., El-Naggar, A. K., Cristiano, R. J., Fang, B., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Merritt, J. A., Mukhopadhyay, T., Nesbitt, J. C., Nguyen, D., Perez-Soler, R, Pisters, K. M. W., Putnam, J. B. Jr., Schrupp, D. S., Shin, D. M., Walsh, G. L., Roth, J. A. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intra-tumor injection of an adenovirus vector expressing wild-type p53 (Ad-p53). *Cancer Gene Therapy*, 7:530-536, 2000. (Highlighted by Gene-Therapy news)
68. Lee, T. V., Anderson, B. W., Peoples, G.E., Castilleja, A., Murray, J.L., Gershenson, D. M. and **Ioannides, C.G.** Identification of activated tumor-Ag-reactive CD8⁺ cells in healthy individuals, *Oncology Reports*, 7:455-466, 2000.

69. Ward, N.E., Stewart, J.R., **Ioannides, C.G.**, and O'Brian, C.A. Oxidant-Induced S-glutathiolation Inactivates PKC- α – A Potential Mechanism of PKC Isozyme Regulation. *Biochemistry*, 39:10319-10329, 2000.
70. Anderson B.W., Peoples, G.E., Murray, J.L., Gillogly, M.A., Gershenson, D.M., and **Ioannides, C.G.** Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. *Clinical Cancer Res.* 6:4192-4200, 2000.
71. Anderson, B.W., Kudelka, A.P., Honda, T., Pollack, M.S., Gershenson, D.M., Gillogly, M.A., Murray, J.L. and **Ioannides, C.G.** Induction of determinant spreading and Th1 responses by in vitro stimulation with HER-2 peptides. *Cancer Immunology Immunotherapy* 49:459-468, 2000.
72. Murray, J. L., Przepiorka, D., and **Ioannides, C. G.** Clinical trials of Her-2/neu-specific vaccines. *Seminars in Oncology*, 26:71-75, 92-100. 2000 (peer-reviewed)
73. Castilleja, A., Ward, N.E., O'Brian, C.A., Swearingen II, B., Swan, E., Gillogly, M.A., Murray, J.L., Kudelka, A.P., Gershenson, D.M. and **Ioannides, C.G.** Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. *Mol. Cell. Biochem.* 217:21-33, 2001.
74. Castilleja, A., Ward, N.E., Epstein, R.B., Kudelka, A.P., Ko, B.K., Efferson, C.L., Gershenson, D.M., O'Brian, C.A. and **Ioannides, C.G.** HER-2 Phosphorylation agonists induce tumor immunogenicity. *Oncology Reports*: 9:929-935, 2002.
75. Kuerer, H., Peoples, G.E., Murray, J.L., Castilleja, A., Gershenson, D.M., and **Ioannides, C.G.** Induction of Th1 responses in axillary lymph nodes of breast cancer patients by HER-2 peptide G89(776-789). *J. Interferon Cytokine Res.*, 22:583-592, 2002.
76. Lee, T.V., Johnston, D.A., Thomakos, N., Honda, T., Efferson, C.L., and **Ioannides, C.G.** Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377) Correlation with the IFN- γ : IL-10 balance. *Anticancer Res.* 22:1481-1490, 2002.
77. Murray, J.L., Gillogly, M., Przepiorka, D., Brewer, H., Ibrahim, N., Booser, D., Hortobagy, G.N., Kudelka, A.P., Grabstein, K., Cheever, M. and **Ioannides, C.G.** Toxicity and induction E75-specific tumor lytic CTL by HER2 peptide E75(369-377) combined with GM-CSF in HLA-A2⁺ patients with metastatic breast and ovarian cancer. A Phase I vaccine trial. *Clinical Cancer Research.* 8:1407-1419, 2002.
78. Castilleja, A., Carter, D., Efferson, C., Ward, E., Fisk, B., Kudelka, A.P., Gershenson, DM, Murray JL, O'Brian, C.A., and **Ioannides, C.G.** Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2 (369-377) selected by molecular modeling of the peptide: HLA-A2. *Journal of Immunology*, 161:3545-3554, 2002.
79. Kim, D.K., Kim, J.H., Kim, Y.T., Kim, J.W., **Ioannides, C.G.** The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate -binding protein peptide cultured with IL-15 and IL-2 against solid tumors. *Yonsei Medical Journal.* 43:691-700, 2002.
80. Efferson, C.L., Schickli, J., Ko, B.K., Mouzi, S., Kawano, K., Palese, P., Garcia-Sastre A., **Ioannides, C.G.** Dendritic cells infected by attenuated influenza virus A/PR8/34 with truncated NS1 protein expressing a HER-2 CTL epitope activated CTL from healthy donors and cancer patients. *Journal of Virology.* 77:7411-7424, 2003.
81. Ko B.K., Kawano, K., Murray, J.L., Kuerer, M. H., Disis, M.L., Efferson, C.L., Peoples, G.E., and **Ioannides, C.G.** Vaccine studies in human breast cancer. *Clinical Cancer Research.* 9:3222-3234, 2003. [Highlighted-Ob-Gyn & NewsRx.net](#))
82. Ko, B.K., Efferson, C.L., Kuerer, H.M., Sahin, A., **Ioannides, C.G.** Stimulation of non-metastatic lymph nodes from a breast cancer patient with HER-2 T-cell epitopes E75 and G89 induced expansion of central memory cells. *International Journal of Oncology.* 24: 1413-1418, 2004.
83. Wool, M.M., Fisher C.M., Ryan, G.B., **Ioannides, C.G.**, Shriver, C.D., Ponniah, S., Peoples, G.E. Direct measurement of peptide specific CD8⁺ T cell using HLA-A2: Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. *Journal of Clinical Immunology* 24: 449-461. 2004.
84. Murray, J.L., Gillogly, M., Lee, J., Kawano, K., Efferson, C.L., Ross, M., Wang, X., Ferrone, S., **Ioannides, C.G.** Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. *Cancer Research*, 64, 5481-5488, 2004.

85. Schellenberger T, Wang M, Gujrati, M., Jayakumar A., Strieter, R.M., Burdick, M.D., El-Naggar A.K., Roberts, D., Efferson, C.L, **Ioannides, C.G.**, Clayman G., and Frederick M.N. BRAK/CXCL144 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. *Cancer Research* 65: 8262-8270. 2004.
86. Woll MM, Hueman MT, Ryan GB, **Ioannides CG**, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based HER2/neu vaccine for prostate cancer. *International Journal of Oncology* 6:1769-1780. 2004.
87. Gillogly et al **Ioannides CG**. li-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. *Cancer Immunol Immunother.* 2004, 53(6):490-6. *AE.Inc refused to include Drs.ioannides and Kuerer as authors.*
88. Kawano, K., Efferson C.L. Peoples G.E., Carter D, Murray, J.L., and **Ioannides C.G.** High sensitivity of TCR^{hi} cells to CH2 groups determine their differentiation or death. *Cancer Research.* 65: 2930-2937. 2005.
89. Efferson, C.L., Kawano, K., Palese, P., Garcia-Sastre, A., and **Ioannides, C.G.**, Stimulation of human T cells by an attenuated Influenza A virus expressing a CTL epitope from the HER-2/neu proto-oncogene results in higher numbers of functional Ag-specific TCR^{hi} cells than stimulation with peptide. Divergent roles of IL-2 and IL-15. *Anticancer Research.* 25: 715-724. 2005.
90. Tsuda, N., Kawano, K., Efferson, C.L., and **Ioannides, C.G.**, Micro RNA-induced inhibition of HER-2 protein expression in ovarian cancer cells. *International Journal of Oncology*, 27, 1299-1306, 2005. *{Highlighted by Gene Therapy News, Cancer Compass-Cancer News, US Women Health Law, released by Ovarian cancer Res.today.*
91. Kawano, K, Ferrone, F, and **Ioannides C.G.**, Functional idiotopes: Tumor antigen - directed expression of homologous epitopes for CD8⁺ cells nested in the unique V_H of anti-Id ? *Cancer Research.* 65:6002-6005 2005. *{ Selected and published in the Perspectives in Cancer Research Findings patented}.*
92. Peoples G.E., Gurney J.M., Ryan, G.B., Woll, M.M., Hueman, M.T. Storrer, C.E., Fisher, C., McLeod, D.G., Shriver, C.D., **Ioannides C. G.**, and Ponniah S., Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high risk breast cancer patients. *The Journal of Clinical Oncology.* 23:7536-7545.2005. *{Selected topic of Editorial Commentary in JCO, 2005, Highlighted}*
93. Hueman M.T, Dehqanzada Z.A, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod, Moul JW, **Ioannides CG**, Ponniah S., Peoples, GE. Clinical trial results of a HER-2/neu peptide (E75)-vaccine for the prevention of PSA recurrence in high-risk prostate cancer patients. *Clinical Cancer Research.* 11:7470-749. 2005.
94. Efferson, C.L., Kawano, K., Sellappan, S., Yu, D., Tsuda N, Garcia-Sastre, A., and **Ioannides. C.G.** Prostate tumor cells infected with a recombinant influenza virus with truncated the non-structural NS1 gene NS1 1-124 activate cytolytic CD8⁺ cells which lyse recognize non-infected tumors. *The Journal of Virology* 80:383-394, 2006-*{Special Emphasis paper, Editor selection } also {Highlighted by Lead-Discovery's Daily Updates-selection 2006. }*
95. Miyahara R, Banerjee S, Kawano K, Efferson C, Tsuda N, Miyahara Y, **Ioannides CG**, Chada S, Ramesh R. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. *Cancer Gene Ther.* 13:753-761, 2006. *{ Highlighted by Gene-Therapy news}*
96. Li, Y, Wong, KK, Matsueda, S, Efferson, CL, Chang DZ, **Ioannides CG** and Tsuda T. Mitogen stimulation activates different signaling pathways in early and late divided T cells as revealed by cDNA microarray analysis. *International Journal of Molecular Medicine.* 12:6557-64. 2006.
97. Tsuda, N, Ishiyama, S, Li, Y, **Ioannides CG**, Abbruzzese, JL and Chang DZ . Synthetic microRNA designed to target Glioma-associated antigen-1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. *Clinical Cancer Research* 12:6557-6664. 2006. *{Selected by Clini-geneTherapy-European Network, (Clinigene.edu); Highlighted in Nature Biotechnology, June, 2007 issue, Cancer News Rx, 2007*
98. Ishiyama, S, Matsueda M, Jones, LA, Efferson, CL, Celestino, J, Schmandt R, **Ioannides CG**, Tsuda N, and Chang DZ. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8⁺ cells in ovarian ascites. *International Journal of Oncology*, 30(4):889-898, 2007
99. Tsuda, N, Chang DZ, Mine, T, Efferson CL, Garcia-Sastre A, Wang X, Ferrone S and **Ioannides C.G** Upregulation of immune stimulatory multi-molecular complexes (ISMMC) formed by ribosome-nascent chain linked to ubiquitin, and heat shock proteins bound to ribosome in taxol-treated tumor

- cells. *Cancer Research*, 67,8378-8387,2007. *Highlighted In Latest ovarian cancerresearch. biojournals.com/ Ovarian%20Cancer.html*
100. **Ioannides CG**. Folate Binding Protein- α -peptide 191-199: Clarification of Its functional significance based on a correct Gene-Bank sequence and on the other FBP(191-199) sequences. *Anticancer Research*, 27, 2511-251,2007. (*Highlighted in News Rx Cancer Law-weekly, Cancer Gene Therapy, 11,2007*)
 101. Peoples GE, Hueman, MT, Mittendorf, EA, Amin , Khoo . SA, Dehqanzada, ZA, Gurney, JM , Woll, MM, Ryan, GB, Storrer, CE, Craig D, **Ioannides, CG**, Ponniah, S. Combined Clinical Trial Results of aHER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: US-Military Cancer Institute Clinical Trial. *Clinical Cancer Research*, 2008. (*Journal Cover page, CCR-journal news Highlighted*).
 102. Li Y, Ishiyama S, Matsueda,S, Tsuda N, and **Ioannides CG**. HER-2 peptides 774 - and 776 - 788 N-terminal-linked with li-tetramer (LRMK) help proliferation of E75-specific CD8⁺ cells. Dependency of help on the side chains of LRMK-extended peptide pointing toward TCR. *Oncology Reports*. 19: 1445-1452, 2008. (*Accolade paper-Figure on Journal Cover Page*).
 103. Mine T, Matsueda S, Li Y, Tokumitsu H, Danes C, Gao H, Wong KK, Wang X, Ferrone S, and Ioannides CG, Breast cancer cells with stem cell markers CD44⁺/CD24^{lo} are eliminated by Numb-1 peptide - activated T cells. *Cancer Immunology Immunotherapy.e-pub.12.2. 2008*.
 104. Li Y, Matsueda M, Efferson CL, Tsuda N, Kawano K, Gao H, and **Ioannides CG**. Distinct preferences in activation of T cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, AE-39 [p776 (Ava-774-788)], AE-47[(Ava-776-788)] and AE-37[p776 (774-788)] peptides could lead to development of personalized cancer vaccines. *Anticancer Research*, 29:41-58, 2009. (*listed in News Rx, Cancer Vaccines. 4, 2009, NHS –UK health service*).
 105. Gates JD, Carmichael MG , Benavides LC, Holmes JP, Hueman MT , Woll MM, **Ioannides CG** , Robson CH , McLeod DG , Ponniah S, Peoples GE . Long-term follow-up assessment of a HER2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients. *J Am Coll Surg*. 208,193-201. 2009.
 106. Tsuda N, Mine T, Ioannides CG, Chang DZ. Synthetic microRNA targeting glioma-associated antigen-1 protein. *Methods Mol Biol*. 487:435-49,2009.
 107. Matsueda S, Hui Gao H, Efferson, CL, Tsuda NT, Ishiyama S, Ioannides MG, Fisk B, Peoples G.E, and **Ioannides CG**. Help for differentiation of E75-TCR⁺ CD8⁺ cells to Perforin-positive cells by N-terminally-LRMK-linked, HER-2 , AE-37 [p776(774-788)] and AE-47 [F7(776-788)] peptides. *Anticancer Research*. 29:2427-2435,2009.
 108. Mine, T, Ferrone, S, Vlastos, G. Peoples GE, Ioannides,CG. **Working hypothesis**: Elimination of cancer stem-cells in solid tumors by immunogene therapy using cancer vaccines and designed duplex-micro RNA. *Current Cancer Therapy Reviews*. 9, 217-226, 2009.
 109. Mine T, Matsueda S, Gao H, Li Y, Wong KK, Ferrone S and **Ioannides CG**. The density of Jagged-1(Jag-1) on the neighboring cell decides phenotype specification of progenitors of Taxol-resistant (TX^{Res}) ovarian cells. *Oncology Reports*.2010.
 110. Li Y, Efferson CL, Ramesh R, Peoples GE, Hwu P, Ioannides CG. A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403-455). *Cancer Immunol Immunother*. 2011 Apr;60(4):515-24.
 111. Li Y, Mine T, Ioannides CG. Short GC-rich RNA similar to miR 1909 and 1915 folds in silico with the 5'-UTR and ORF of Notch and responders: potential for the elimination of cancer stem cells. *Oncol Rep*. 2010 Dec;24(6):1443-53.
 112. Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, **Ioannides CG**, Ponniah S, Peoples GE. Folate receptor α : a storied past and promising future in immunotherapy. *Hum Vaccin*. 2011 Feb;7(2):183-90. Epub 2011 Feb 1. Review.
 113. Ramesh R, **Ioannides CG**, Roth JA, Chada S. Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer. *Methods Mol Biol*. 2010;651:241-70
 114. Bernatchez C, Zhu K, Li Y, Andersson H, Ioannides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of survivin differentially stimulate T-cell responses in different individuals. *Vaccine*. 2011 Apr 5;29(16):3021-30.

Book Chapters.

1. 115.Papamichail, M., **Ioannides, C.G.**, Leventakou, A., Tsawdaroglou, N., and Sekeris, C.E. The detection of glucocorticoid receptors in breast cancer by immunochemical and biochemical methods. *Excerpta Medica. Intern. Congr. Series*, 484:321-325, 1978
2. 116.Papamichail, M., **Ioannides, C.G.**, Tsawdaroglou, N., and Sekeris, C.E. Glucocorticoid receptors in human lymphocytes and lympho-proliferative disorders. *Proc. 2nd Intl Lymphoma Conference* 1:137-148, 1981
3. 117.Tsiapalis, C.M., **Ioannides, C.G.**, Trangas, T., Courtis, N., Pangalis, G.A., Cosmides, H.V., and Papamichail, M. Poly(A) polymerase and poly(A) nuclease levels in human ALL and CLL lymphocytes. In: *Advances in Comparative Leukemia Research* (Yohn, D.A., and Blakeslee, J.R.,Ed) 343-344, 1981.
4. 118.Papamichail, M., Trangas, T., Courtis, N., **Ioannides, C.G.**, Cosmides, H.V., Pangalis, G.A., and Tsiapalis, C.M. Poly(A) polymerase levels in leukemia. In: *Modern Trends in Human Leukemia*. (Neth, Gallo, Greaves, Moore, and Winkler, Ed). Springer Verlag, Berlin, Heidelberg 28-29, 1984.
5. 119.Platsoucas, C.D., **Ioannides, C.G.**, Itoh, K., Fox, F.E., Pahwa, R., and Good, R.A. Gamma T cell receptors in man and mouse: Identification by an antipeptide gamma chain specific monoclonal antibody. In: *The T Cell Receptor*. UCLA Symposia on Molecular and Cellular Biology, New Series, Eds. Kappler, J., and Davis, M., Alan R. Liss Inc., New York, NY 73:77-86, 1988.
6. 120.Freedman, R.S., and **Ioannides, C.G.** Biological response modifiers in the treatment of gynecologic malignancies. *Cancer Bulletin*. 42:98-105, 1990.
7. 121.O'Brian, C. A., Ward, N. E., Dong, Z and **Ioannides, C. G.** Potential strategies of chemoprevention through modulation of PKC activity. *Cellular and molecular targets for chemoprevention*. (Vernon E. Stiele, Ed.) CRC Press, Boca-Raton, 161-170, 1992.
8. 122.**Ioannides, C.G.**, Fisk, B., Jerome, K.R., Chesak, B., Irimura, T., Wharton, J.T. and Finn, O.J. Ovarian tumors reacting cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins. "Ovarian Cancer 3," Chapter, (Sharp, F., Mason, P., Berek, J.& Blackett, A. Ed). Chapman and Hall, London, 31:317-330, 1994.
9. 123.Pollack, M. S. and **Ioannides, C. G.** Preparation of human non-lymphoid cultured tumor cells for histocompatibility antigen typing. (*ASHI Laboratory Manual*), 3rd Edition, (Nikaein, A, Ed.) (ASHI Laboratories Publishers), IIB, pp 501-509, 1994.
10. 124.**Ioannides, C.G.**, Fan, D., and Whiteside, T.L. Immunotherapy of Cancer. Golematis, B.H., (Ed). *Surgical Pathology: "Diseases of the Digestive System"* 131-147, 1995
11. 125.**Ioannides, C.G.**, and Grimm, E.A. Tumor Immunity, in "Principles of Clinical Immunology", 1st Edition, Chapter 22, (Rich, R., Shearer, W.T., Strober, W., Fleisher, T.A.& Schwartz, B.D. Ed.) Mosby. St. Louis, 333-349, 1995.
12. 126.O'Brian, C.A., Gravitt, K.R., Ward, N.E., Gupta, K.P., Bergman, P.J., and **Ioannides, C.G.** Protein kinase C activation and the intrinsic drug resistance of human colon cancer in "Drug Resistance in Oncology", Bernard, S.D. Ed 215-225, 1997.

Editorials and commentaries.

1. 127.Ioannides, C. G. Concepts in developing human tumor vaccines, in Human Tumor Vaccines. *Intl. Rev. Immunol.* 7:1-2, 1991, (Editorial).
2. 128.Ioannides, C. G., and Den Otter, W. V. Concepts in Immunotherapy of Cancer: Introduction. *In Vivo* 5:551-552, 1991, (Editorial).
3. 129.Ioannides, C.G. *Editorial Commentary "Breast Diseases: A Yearbook Quarterly"* Balch, C.M., Dodd, G.D., Henderson, I.C., Perez, C.A., editors Mosby, St. Louis, 5:39-40, 1994.
4. 130.Tuttle, T.M and Ioannides, C.G. *Editorial Commentary "Breast Diseases: A Yearbook Quarterly"* Balch, C.M., Dodd, G.D., Henderson, I.C., Perez, C.A., editors Mosby, St. Louis, 7:371-372, 1997.
5. 131.Ioannides, C.G. *Editorial Commentary "Breast Diseases: A Yearbook Quarterly"* Balch, C.M., Dodd, G.D., Henderson, I.C., Perez, C.A., editors Mosby, St. Louis, 8:26-27, 1997.
6. 132.Johnston, D., and Ioannides, C.G. *Editorial Commentary "Breast Diseases: A Yearbook Quarterly"* Balch, C.M., Dodd, G.D., Henderson, I.C., Perez, C.A., editors Mosby, St. Louis, 8:323-324, 1998.
7. 133.Dong-Kyu Kim and Ioannides, C.G. *Editorial Commentary "Breast Diseases"*, 9:257-258, 1998.
8. 134.Dong-Kyu, K and Ioannides, C.G. *Editorial Commentary "Breast Diseases: A Yearbook Quarterly"*, 9(4), 356-357, 1999.
9. 135.Vlastos, G. and Ioannides, C. G. *Editorial Commentary "Breast Diseases"*, 10:(4), 417, 2000.
10. 136.Vlastos, G. and Ioannides, C. G. *Editorial Commentary "Breast Diseases"*, 10:(4), 419, 2000.
11. 137.Ko, B.K. and Ioannides, C.G. *Editorial Commentary "Breast Diseases"*, 11(5), 2001.

12. 138. Ioannides CG, *Recommendations for Future Multi-Forums as Jean Monet Study & Research Centers of Europe*, Proc of 3rd International Conference: Interdisciplinary Education, ICIE'07, S7, pp. 1-2.
13. 139. Ioannides CG. *Foreword*. Hercules/Heraclides and liberation of Prometheus. In search for new Heraclides. 4th International Conference on Interdisciplinarity in Education ICIE'09. Vilnius Lithuania- in press, 2010.
14. 140. The European Script 2011.

TEACHING AIDS

1. *Syllabus*: Peptides and Vaccines: Gyn-Oncol, Fellows Training program. 2001.
 2. *Syllabus*: Vaccines in solid tumors. GSBS, Cancer Immunotherapy, (Dong-Kyu Kim and C.G. Ioannides 1999, 2001).
 3. Immunology Teaching Aid for Clinical Fellows and Residents, (R.S. Freedman, and C. G. Ioannides), 1989, 1990, 1991
-

ARTICLES IN LOCAL PUBLICATIONS ROMANIA AND GREECE

Cantacuzino Institute (1972-1978- published extended abstracts, complete data publication was not permitted because of the sensitive nature of the topic) and Hellenic Anticancer Institute, (1978-1981)

1. Teodorescu, G., Zamfir, M., Gheordunescu, V., and Ioannides, C.G. Studies for the standardization of culture media and obtaining of new peptones. *Ses. Sti. Inst. Cantacuzino, XI*, 38-40, 1973.
2. Teodorescu, G., and Ioannides, C.G. New peptones obtained by triptical and acid hydrolysis of casein and meat. *Ses. Sti. Inst. Cantacuzino, XII*, 139-140, 1974.
3. Teodorescu, G., Ioannides, C.G., Ionescu, A., and Szabados, J. Peptones and nutrient extracts for bacteriological media obtained in the Cantacuzino Institute. *Ses. Sti. Inst. Cantacuzino, XIII*, 189-191, 1975.
4. Teodorescu, G., Ioannides, C.G., and Ionescu, A. Technological studies for obtaining dry peptones and nutrient extracts. *Ses. Sti. Inst. Cantacuzino. XIV*, 75-77, 1976.
5. Gaspar, A., and Ioannides, C.G. The sialic acid surface component of influenza virus type C. *Ses. Sti. Inst. Cantacuzino. XV*, 126-127, 1977.
6. Ardeleanu, J., Ioannides, C. G., and Niculescu, I. Th. Studies on the neuraminidase of Clostridium Perfringens. *Ses. Sti. Inst. Cantacuzino. XVI*, 128-129, 1977.
7. Zilisteanu, E., Niculescu, I. Th., Matepiuc, M., Cretescu, L., Crainic, R., Sperantia, C., Grobnicu, M., Botez, D., Anghel, Cl., Dumitrescu, R., and Ioannides, C.G. Evaluation of the immunization with influenza vaccine. Determination of the sero-conversion and of the titre of the anti-haemagglutinin antibodies as function of dose and route of administration. *Ses. St. Inst. Cantacuzino, XVII*, 5-8, 1978.
8. Trangas, T., Ioannides, C.G., Courtis, N., Papamichail, M., and Tsiapalis, C.M. Poly(A) nuclease activity alteration in response to physiological stimuli in human lymphocytes. *Hellenic Biophysical and Biochemical Newsletter*, 17:3, 1981.
9. Tsiapalis, C.M., Trangas, T., Ioannides, C.G., Courtis, N., Gounaris, A., and Papamichail, M. Poly(A) polymerase activity measurements with various initiators in human lymphocytes. *Hellenic Biochemical and Biophysical Newsletter* 17:4, 1981.
10. Ioannides, C.G. Biologic functions of glucocorticoid receptors in lymphocytes, *Ph.D. Thesis, University of Athens, Press, 1981*.

Manuscripts in Preparation

1. Efferson C.L Kawano, K., Peoples G.E., Carter D, and Ioannides C.G. High sensitivity of TCR^{hi} cells to CH2 groups determine their differentiation or death.
2. Li Y and Ioannides CG. Mutations in mirtronic miR802 increase its specificity for Notch-1 ORF and 3'-UTR.

ABSTRACTS PRESENTED IN NATIONAL SYMPOSIA, 2000-2007.

1. Murray, J. L., Gillogly, M. A., Ross, M., and **Ioannides, C. G.** Enhanced tumor specific cellular immunity by HLA-A2 (A2) restricted peptides derived from anti-idotype (α ID) antibody (Ab2) variable regions mimicking the melanoma proteoglycan antigen (MPG). *AACR, 4/ 1,2000*. Proc. AACR,2000. Published.
2. **Ioannides, C. G.**, Tuttle, T. M., Peoples, G.E., Honda, T., Kim,K-K, Kudelka, AP, Murray, JL & Gershenson, D.M. Epitope-Specific T-Cell Immunity to Breast Cancer, DOD Breast Cancer Research Program, 6/ 8-12, 2000, Meeting Proceedings, Vol. 2, p. 146-147.
3. Gillogly, M.A., Murray, J.L., Castilleja, A., Gershenson, D.M., and **Ioannides, G.C.**, Induction of immunity to HER-2 by TCR directed variants of the CTL Epitope E75. The FASEB J.14, A147, 2000.
4. Peoples, G.,Anderson, B., Kim, D., and **Ioannides, G.C.**, The Immune Response to a Folate Binding protein-derived peptide/dendritic cell vaccine in cancer patients and healthy volunteers. *61st Annual Meeting, Society of University Surgeons, March 2000, New Orleans, LA.*
5. Gillogly, M.A., Sahin, A.A., **Ioannides, C.G.**, and Murray, J.L. Cellular immune responses to immunodominant HER-2/Neu helper peptides in patients with ductal carcinoma *in situ* (DCIS). 23rd Annual Meeting *Breast Cancer Symposium, Immunol. Immunother. October, 2000*, San Antonio, TX.
6. Ryan, G.B., Fisk, B.A., **Ioannides, C.G.**, Sesterhenn, I.A., Moul, J.W., McLeod, D.G., and Peoples, G.E. Preclinical Testing of a Peptide-based, HER2/NEU Vaccine in prostate cancer. *Proc. AACR, 42, A3668, p.681, 2001.*
7. Swan, E.A., Custer, J.L., Lee, T.V., Kuerer, H.M., Peoples, G.E., Gershenson, D.M., **Ioannides, C.G.** Helper effects for HER-2 specific CTL induction by a HER-2 peptide. *The FASEB J. 15(4), 521.2, A657, 2001.* **{Symposium presentation, top 10%}**
8. Carter, D., Campbell, M., Ward, N.E., O'Brian, C.A., Gershenson, D.M. and **Ioannides, C.G.** Induction of cancer immunity by targeted hydrophobic ladders in the tumor antigen. *The FASEB J.15(4), 946.18, A1200, 2001.* **{Symposium presentation, top 10%.**
9. Efferson, C., Schickll, J., Ko, B..K., Garcia,-Sastre, A., Mouzi, S., Palese, P. and **Ioannides, C.G.** Recombinant A virus with truncated NS1 expressing a HER-2 peptide is immunogenic for induction and expansion of functional anti-tumor human CTL. *19th Texas Regional Immunology Conference, Oklahoma, OK, 2001.*
10. Kuerer, H., Peoples, A., Sahin, J., Murray, J., Singletary, E., Castilleja, A., Hunt, K., Gershenson, D., and **Ioannides. C.G.** Axillary lymph node (LN) cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. *62th Annual Meeting Society of Surgical Oncology, 22:583-592, 2002.*
11. Ward, N.E., Carter, D., Castelleja, A., Fisk, B., O'Brian, C.A., **Ioannides, C.G.** CTL induced by a variant of the of the HER-2 CTL epitope E75 are resistant to apoptosis mediated by E75. *The FASEB J 16(4) A.246.19, 2002.* **{Symposium presentation, top 10%}**
12. Efferson, C.L., Schickli, J., Byung, K.K., Garcia-Sastre, A., Mouzi, S., Palese, P., **Ioannides, C.G.** Recombinant influenza A virus with truncated NS1 expressing HER-2 peptide E75 is immunogenic for differentiation and expansion of functional anti-tumor human CTL. *The FASEB J. 16(4) A.246.8, 2002.* **{Symposium presentation top 10%}**
13. Lee, J.E., Abdalla, J., Miyamoto, Y.J., Grimm, E.A., Reveille, J.D., Mansfield, P.F., Gershenwald, J.E., Ross, M.I., McIntyre, B.W., **Ioannides, C.G.** U.T. M.D. Anderson Cancer Center. Association of the HLA class II alleles DQB1*0301 and DRB1*1101 with low interferon- γ production in lymphocytes from melanoma patients. *Proc. AACR 43, A4822, p 974, 2002.*
14. **Ioannides, C.G.**, Efferson, C.L., Campbell, M.E., Carter, D., Gershenson, D.M., Kudelka, A.P., Murray, J.L., O'Brian, C.A. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2 (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. *Proceedings, DOD Era of Hope 2002.* **.
15. Efferson, C.L., Ward, N.E., Kawano, K., Kudelka, A.P., O'Brian, C.A., **Ioannides, C.G.**, Murray, J.L. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2 (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. *Proc.iSTBC, San Diego, CA, 2002.* ***.
16. Kawano, K., Efferson, C.L., Hannay, J.A.F., Kudelka, A.P., **Ioannides, C.G.**, Murray, J.L. Hydrophobically appended tumor antigens induce high affinity cytotoxic T cells from ovarian tumor associated lymphocytes. *Proc.iSTBC, San Diego, CA, 2002.* **{Symposium presentation, top 10%}**
17. Kawano K., Efferson C.L., Murray J.L., **Ioannides C.G.** Expansion and differentiation of vaccine-induced high-affinity CD8+ T cells to HER2 requires distinct variants of the tumor antigen. *FASEB J. 17(7):C75, 2003.*
18. Efferson C.L., Kawano K., Kudelka A.P., Murray J.L., **Ioannides C.G.** Hydrophobically appended tumor antigens induce high affinity cytotoxic T cells from ovarian tumor associated lymphocytes. *FASEB J. 17(7):C78, 2003.*
19. Kawano K., N. Tsuda, K. Ushijima, T. Kamura, and **C. G. Ioannides.** Sensitivity of high-TCR-density CD8+ cells to a CH2 appended to tumor antigen determines their differentiation or death. *Acta Obstetrica Et Gynaecologica Japonica 2005 57:2, 805.* **{Symposium Presentation}**
20. Kawano K., N. Tsuda, K. Ushijima, T. Kamura, and **C. G. Ioannides.** Sensitivity of high-TCR-density CD8+ cells to a CH2 appended to tumor antigen determines their differentiation or death. *Acta Obstetrica et Gynaecologica Japonica 2005 57:2, 805.* **{Symposium Presentation}**
21. Murray, J.L., Kawano, K., Efferson, C. L., **Ioannides, C. G.** Induction of medium/high affinity HLA-A2 restricted E75-TCR+ specified cells in patients immunized with HER-2/neu peptide vaccine. *Proc. AACR 2003. 44 2nd edition: 765-766.*

22. Murray, J. L., Efferson, C. L., Kawano, K., Schickli, J., Palese, P., Garcia-Sastre, A., and **Ioannides, C. G.** Activation of tumor antigen specific CTL by myeloid DC infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. *J. Immunother.* 2003: 26(6) S11.
23. **Efferson CL**, Kawano K., Murray J.L., Palese P., Garcia-Sastre A., and **Ioannides C.G.** Interaction of dendritic cells within influenza virus proteins results in IL-12 and IFN- γ induction. *The FASEB J.* 2004. 18(4): A63.
24. **Kawano K**, Efferson C.L., Kudelka A.P., Murray J.L., and **Ioannides C.G.** Expansion and differentiation of TCR α cells to functional CTL regulated by Methylene groups (CH₂) in the tumor Ag. *The FASEB J.* 2004. 18(4): A62-63.
25. **Efferson, C. L.**, Kawano, K., Sellappan, S., Yu, D., Babaian, R., Palese, P., Garcia-Sastre, A., **Ioannides, C. G.**, Murray, J. L. Prostate tumor cells infected with a recombinant influenza virus with truncated NS1 gene NS1 (1-126) activate cytolytic CD8⁺ cells which recognize non-infected tumors. *J. Immunother.* 2004: 27(6) S53.
26. **Kawano, K** Efferson,CL, **Ioannides,CG**, Humphreys,RE , James Murray JL. Enhanced TH-1 Responses by Novel li-Key HER2/neu Peptides in Breast Cancer Patients. *J. Immunother.* 2004: 27(6) S71.(correction-10/2007).
27. Miyahara, R., Banerjee, S., Kawano, K., Efferson, C., Tsuda, N., Miyahara, Y., **Ioannides, C.G.**, Chada, S., and Ramesh, R. Induction of anticancer immunity by MDA-7/IL-24. *AACR.* 2005.
28. **Efferson, C.L.**, Kawano, K., Tsuda, N., Murray, J.L., and **Ioannides, C.G.** Short peptides interact with natural TLR-2 agonists. *FASEB. J.* 2005.
29. **Tsuda, N.**, Efferson, C.L., Frederick, M., Gonzalez, D., Celestino, J., Schmandt, R., Garcia-Sastre, A., and **Ioannides, C.G.** Polysomal RNA-mediated cross-priming of Tumor Ag Specific CTL *FASEB.* 2005.
{Symposium Presentation, top 10%}
30. Tsuda N, Ohtani S, Efferson, CL, Schmandt, R, Celestino, J, Gonzales D, Palese, P Garcia-Sastre A, **Ioannides CG**, Novel therapeutic approaches to ovarian cancer targeting poly-RNA. *DOD Meeting Era of Hope, Philadelphia, PA, June 2005. (DOD Travel Award)*
31. Chang DZ, Tsuda N, Ohtani S, Palese, P Garcia-Sastre A, **Ioannides CG**, Abbruzesse, J. Her-2 nascent polypeptide chain bound on ribosomes translating influenza virus proteins induce differentiation of CD8⁺ cells. *Sloan Kettering Meeting on Cancer Vaccines, 10/ 2005.*
32. Chang DZ, Tsuda N, Abbruzesse, J and **Ioannides, CG.** Proc. ISBtC- Alexandria, VA, November, 2005.
33. **Efferson, C.L. et al**, AACR. 2006 {Symposium presentation 2006.} (Travel Award Merck Corporation).
34. Yufeng Li et al, AACR. March 2006 (Travel Award Graduate School- first author and presenter is first year Graduate Student)
35. Tsuda N, et al, FASEB J. 2006. (sick-lost track)
36. Peoples GE, Hueman, MT, Mittendorf, EA, Amin , Khoo . SA, Dehqanzada, ZA, Gurney, JM , Woll, MM, Ryan, GB, Storrer, CE, Craig D, **Ioannides, CG**, Ponniah, S. Combined clinical trial results of aHER2/neu (E75) vaccine for the prevention of recurrence in high-risk BC patients. 27th San Antonio Breast Cancer Meeting, 12/2006. **{Symposium presentation top 10%- plus news AP,CNN, Dow-Jones, etc}**
37. Mine, T, Matsueda, S, Tokumitsu H, Chang DZ, **Ioannides CG.** Elimination of drug-resistant cancer stem-like cells (C-St-C) by Notch and Numb-peptide activated T cells. Proc. AACR-Late Breaking News Abstract. 07-LBA-8915-AACR. 2007.
38. Yufeng Li , Clayton L. Efferson CL Peoples GE, **Ioannides CG** . Negatively charged peptides bind to TLR-2 agonist PGN and synergistically amplify TLR-2 activation of cytokine induction in antigen-presenting cells. ISTBC-2007-submitted 7/22/07. **Travel Award Graduate School- 1stauthor and presenter is 2nd year Graduate Student)**

Selected Abstracts: 1979-1999.

1. Papamichail, M., Tsokos, G., **Ioannides, C.G.**, Leventakou, A., Tsawdaroglou, N., and Sekeris, C.E. The detection of glucocorticoid receptors in breast cancer by immunocytochemical and biochemical methods. 8th Intl Symposium: *Biological Characterization of Human Tumors.* Athens. 5/8-11/ 1979.
2. Papamichail, M., **Ioannides, C.G.**, Tsawdaroglou, N., and Sekeris, C.E. The use o specific antisera to detect glucocorticoid receptors in different cell types. 1st Intl Congress on Hormones, and Cancer. Rome, 10/ 3-6/ 1979.
3. Papamichail, M., Agnantis, N., **Ioannides, C.G.**, Garras, J., and Sekeris, C.E. Detection of glucocorticoid receptors in breast cancer. Comparison of biochemical and immunochemical methods. 4th Intl Symposium: *Prevention and Detection of Cancer.* London, 1980.
4. Agnantis, N., Papamichail, M., **Ioannides, C.G.**, Garras, J., and Sekeris, C.E. Glucocorticoid receptors and histological parameters in breast tumors and tumor-like conditions. 12th Intl Meeting: *Mammary Cancer in Experimental Animals and Man.* Maastricht 5/11-14/1980.
5. Papamichail, M., **Ioannides, C.G.**, Trangas, T., Courtis, M., Petraki, H., Pangalis, G., Tsiapalis, C. Poly(A)-polymerase and poly(A)- nuclease levels in normal PHA stimulated and leukemic lymphocytes. 6th Meeting of Intl Society of Haematology. Athens, 8/ 30-9/4/1981.

6. Trangas, T., **Ioannides, C.G.**, Courtis, N., Gounaris, A., Papamichail, M., and Tsiapalis, C. Early decrease of poly(A)-endoribonuclease in human PHA-stimulated lymphocytes. *14th Intl Leukocyte Culture Conference. Heidelberg, 1981.*
7. Tsiapalis, C.M., **Ioannides, C.G.**, Trangas, T., Courtis, N., Pangalis, G., Cosmides, H., and Papamichail, M. Poly(A)-polymerase and poly(A)-nuclease levels in human lymphoid cells from acute and chronic lymphocyte leukemia. *Intl Symposium : Comparative Research on Leukemia and Related Diseases, UCLA, Los Angeles. 8/31-9/4/ 1981.*
8. Papamichail, M., **Ioannides, C.G.**, Tsawdaroglou, N., and Sekeris, C. Glucocorticoid receptors in human lymphocytes and lymphoproliferative disorders. *2nd Intl Lymphoma Conference. Athens, 4/1/ 1981.*
9. **Ioannides, C.G.**, Tsawdaroglou, N., Papamichail, M., and Sekeris, C. Biological functions of glucocorticoid receptors in lymphocytes. *FEBS Meeting: Cell Function and Differentiation. Athens. 1982.*
10. **Ioannides, C.G.**, Petraki-Ravasopoulou, H., and Papamichail, M. Production of a T-cell suppressor factor by MOLT 3-cell line. *5th European Immunology Meeting. Istanbul. 6/ 1-4/1982.*
11. Trangas, T., Courtis, N., **Ioannides, C.G.**, Pangalis, G., Cosmides, H., Papamichail, M., and Tsiapalis, C. Poly(A)-polymerase and poly(A)-nuclease levels in acute and chronic leukemias. *1st Intl Congress on Cancer Biology. Thessaloniki, 12/ 2-5/1982.*
12. Petraki, H., **Ioannides, C.G.**, Filli, S., and Papamichail, M. Loss and reappearance of transferrin receptor in leukemic cell lines during differentiation. *16th FEBS Meeting. Moscow, 1984.*
13. **Ioannides, C.G.**, Baxevanis, C., Papastergiou, N., and Papamichail, M. Regulation of murine MLR responses by human IgG Fc and pFc fragments. *16th FEBS Meeting. Moscow, 1984.*
14. Baxevanis, C., **Ioannides, C.G.**, Papastergiou, N., and Papamichail, M. Murine T cell activation by the human IgG Fc and pFc fragments. *16th FEBS Meeting. Moscow, 1984.*
15. Baxevanis, C., **Ioannides, C.G.**, and Papamichail, M. Demonstration of activation specific interactions between T lymphocytes and macrophages by human IgG Fc fragment. *7th European Immunology Meeting, Jerusalem, Israel. 9/ 1-5/1985.*
16. **Ioannides, C.G.**, Itoh, K., Pahwa, R., Good, R., and Platsoucas C.D. Identification of a T3-associated putative second T-cell antigen receptor by an antipeptide g-chain specific mAb *FASEB 1987. Federation Proceedings, 46:466, 1987.*
17. Platsoucas, C.D., Itoh, K., Pahwa, R., Good, R., and **Ioannides, C.G.**, Identification of a putative second T cell antigen receptor in mouse and man by an antipeptide g-chain specific mAb. *UCLA Symposia: The T-cell antigen Receptor, Keystone, Colorado. 1987. J. Cell. Biochem. 11D:216, 1987.*
18. Itoh, K., **Ioannides, C.G.**, Suzuki, R., Platsoucas, C.D. and Balch, C.M. A novel antigen expressed on murine thymocytes and cloned NK cells. *UCLA Symposia: The T cell Receptor, Keystone, Colorado. 1987. J. Cell. Biochem. 11:D232, 1987.*
19. **Ioannides, C.G.**, Itoh, K., Fox F.E., and Platsoucas C.D. Gamma T cell antigen receptors on human and mouse lymphocytes. Identification of a non-disulfide linked g- g- receptor. *Texas Immunology Conference. Austin, 11,1987.*
20. Freedman, R.S., Bowen J.M, Wallace, S., Edwards, C.L., Wharton, J.T., **Ioannides, C.G.**, Atkinson, N., Lamki, L., Podolov, D., Reuben, J., Lotzova, E. Pre-irradiation intralymphatic viral oncolysate (ILVO) in cervix carcinoma patients with metastatic lymph node involvement. *AACR, New Orleans, 1988.*
21. Morkowski, J., Nanno, M., Itoh, K., **Ioannides, C.G.**, Becker, F.F., and Platsoucas, C.D. A non-disulfide-linked gamma T cell receptor expressed on a murine lymphoma T cell line. *FASEB, Las Vegas, 1988. Federation Proceedings, 2:447. (Presented in plenary session).*
22. **Ioannides, C.G.**, O'Brian, C.A., Patenia, R., and Freedman, R.S. Identification of tumor growth and lymphocyte activation-inhibitory effects of viral oncolysates. *Texas Carcinogenesis Meeting, Galveston, Texas. 11/ 1988.*
23. **Ioannides C.G.**, Freedman R.S, and Platsoucas, C.D. Activation of a human CD4⁺ T cell clone by the OKT4 mAb. *Texas Immunology Conference, Galveston, 11/ 1988. (Abstract #53, p. 31).*
24. **Ioannides, C.G.**, Platsoucas, C., Bowen, J., Wharton, J., Patenia, R., Scott W., and Freedman, R.S. T cell inhibitory and stimulatory components in viral oncolysates employed for active immunotherapy in ovarian cancer. *Texas Immunology Conference, Galveston 11/1988. (Abstract #60, p. 35).*
25. Nanno M., Seki, H., Cheng, P-F, **Ioannides, C.G.**, Balch, C.M., Itoh, K., and Platsoucas, C.D. Tumor infiltrating lymphocytes expressing the gd T cell antigen receptor (TCR). *Texas Immunology Conference, Galveston, 11/ 1988. (presented in plenary session).*
26. Seki H., Nanno M., Cheng, P-F, Itoh, K., **Ioannides, C.G.**, Platsoucas, C.D. Disulfide and non-disulfide linked g-d T cell antigen receptors (TCR) expressed on T cell clones from normal donors. Heterogeneity of the d chain. *Texas Immunology Conference, Galveston. 11/ 1988. (Abstract #50, p. 30).*
27. Mathoudakis, G., **Ioannides, C.G.**, Seki, H., Kruziel, E., and Platsoucas, C.D. Distinct epitopes on the LFA-1 molecules involved in adhesion and cell proliferation. *Identification with a new monoclonal antibody. Texas Immunology Conference, Galveston, 11/1988.*
28. Nanno, M., Seki, H., Cheng, P-F., **Ioannides, C.G.**, Balch, C.M., Itoh, K., and Platsoucas, C.D. Tumor infiltrating lymphocytes expressing the gd TCR. *FASEB, New Orleans, LA, 1989. The FASEB J. 3:507, 1989.*
29. Yang L-S, Mathioudakis, G., **Ioannides, C.G.**, and Platsoucas, C.D. LDA-4: A new disulfide-linked human T cell differentiation antigen. *FASEB, New Orleans, LA, 1989. The FASEB J. 3:1109, 1989.*

30. Seki H., Nanno, M., Cheng, P-F, Itoh, K, **Ioannides, C.G.**, and Platsoucas, C.D. Molecular heterogeneity of the gd-TCR expressed on T cell clones from normal donors. *FASEB, New Orleans, LA, 1989. The FASEB J. 3:484, 1989.*
31. Mathioudakis, G., **Ioannides, C.G.**, Seki, H., Kruziel, E., and Platsoucas, C.D. Distinct epitopes of the LFA-1 molecule are involved in adhesion and cell proliferation. *FASEB, New Orleans, LA, 1989. The FASEB J. 3:513, 1989.*
32. **Ioannides, C.G.**, Freedman, R.S, and Platsoucas, C.D. OKT4 monoclonal antibody induced activation of an autoreactive T cell clone. *FASEB, New Orleans, LA, 1989. The FASEB J., 3:513, 1989.*
33. **Ioannides, C.G.**, Patenia, R., Bowen, J.M, Fox, F., Platsoucas, C.D., Wharton, J.T., and Freedman, R.S. Stimulatory and inhibitory components of T cell activation in ovarian tumor viral oncolysates. *Proc. Internatl Symposium: Critical Determinants in Cancer Progression and Metastasis. Houston, Texas. 3/ 6-10/1989 p. 107.*
34. Mathioudakis, G., **Ioannides, C.G.**, Seki, H., Kruziel, E., and Platsoucas, C.D. Adhesion and cell proliferation mediated by the LFA-1 antigen involve distinct epitopes on the LFA-1 molecule. *J. Cell Biol. 1989.*
35. **Ioannides, C.G.**, Freedman, R.S., Morris, M., and Platsoucas, C.D. T cell modulation in ovarian cancer patients receiving IV rIL-2 (Cetus) followed by combination of IV+ intraperitoneal rIL-2+IP viral oncolysate. *Proc. AACR. 31, 175, 1990.*
36. Morris, M., Freedman, R.S. **Ioannides, C.G.**, Lotzova, E., Edwards, C.L., and Wharton, J.T. Phase I trial of continuous IV infusion interleukin-2 (rIL-2 Cetus) and fixed bolus doses of intraperitoneal rIL-2 and viral oncolysate in patients with advanced epithelial ovarian cancer. *Proc. ASCO, 9:626, 1990.*
37. Freedman, R., **Ioannides, C.G.**, Tomasovic, B., Patenia, R., Kim, Y-P, Zhang, H-Z, Edwards, C.L., and Wharton, J.T. Partial characterization of a human anti-ovarian tumor monoclonal antibody. *Proc. AACR, 31, 287, 1990.*
38. **Ioannides, C.G.**, Freedman, R.S., and Platsoucas, C.D. Autologous tumor-specific TIL in ovarian cancer. *The FASEB J. 4:A2021, 1990, Abstract #1893.*
39. Freedman, R.S., Patenia R, Rashed, S., Platsoucas, C.D., and **Ioannides, C.G.** T cell functions in ovarian cancer patients treated with tumor cell vaccines. *The FASEB J. 4:A1718, 1990, Abstract #136.*
40. O'Brian, C.A., Liskamp, R., and **Ioannides, C.G.** Inhibition of IL-2R induction and IL-2 production in Jurkat cells by a novel protein kinase C inhibitor N-m- KRTLRL. *The FASEB J. 4:A1738, 1990. Abstract #258.*
41. Nanno, M., Seki, H., Itoh, K., **Ioannides, C.G.**, and Platsoucas, C.D. T cell antigen receptor gd on human T cells. *Annual Meeting of Japanese Association of Immunologists, 1989.*
42. Freedman, R.S., **Ioannides, C.G.**, Tomasovic, B., Patenia, R., Zhang, H-Z, and Edwards, C.L. Development of a cell surface reacting human monoclonal antibody agent in ovarian carcinoma. *1st International Conference: Human Antibodies and Hybridomas, 1990, p. 50, Abstract #6.*
43. Nanno, M., Seki, H., **Ioannides, C.G.**, Itoh, K., Day, N.K., Good, R.A., Platsoucas, C.D. Nondisulfide-linked gd T cell receptors are primarily expressed on T cell lines derived from patients with primary immunodeficiency disorders. *The FASEB J. 4(7): Abstract 31, 1990.*
44. **Ioannides, C.G.**, Edwards, C.L., Wharton, J.T., and Freedman, R.S. Ovarian tumor-associated lymphocytes (TAL): modulation of their lytic function and characterization of their target specificity (meeting abstract). *Proc. Felix Rutledge Society, 22nd Annual Meeting. 5/23-25/ 1991, Houston, TX p. 57, 1991.*
45. Freedman, R. S., and **Ioannides, C. G.** Cytotoxic T cell clones from ovarian TIL recognize multiple antigenic epitopes on autologous tumor cells. *The FASEB J, 5(6), A173, 1991.*
46. **Ioannides, C. G.**, and Freedman, R. S. Preferential expression of TCR Vb in tumor specific CTL from ovarian TIL. *The FASEB J, 5(6), A1712, 1991.*
47. **Ioannides, C. G.**, Platsoucas, C. D., Edwards, C. L., and Freedman, R. S. Tumor specific CTL from ovarian ascitic infiltrating lymphocytes. *Vol. 82, Abstract #1456, Proc. AACR, 1991.*
48. **Ioannides, C. G.**, Fan, D., Itoh, K., Edwards, C. L., and Freedman, R. S. Differential effects of TNF- a and IL-4 on expansion of lymphocytes infiltrating ovarian malignant ascites. *Proc. AACR, 1991.*
49. **Ioannides, C.G.**, Freedman, R.S., Ioannides, M.G., Fisk, B., and O'Brian, C.A. CTL clones isolated from ovarian tumor infiltrating lymphocytes can recognize peptides with sequences corresponding to the HER2/Neu gene product. *The FASEB J. 6(5): A.1404, 1992.*
50. **Ioannides, C.G.**, Fisk, B., Jerome, K.R., Irimura, T., Freedman, R.S., and Finn, O.J. Cytotoxic T cells isolated from ovarian tumor infiltrating lymphocytes can recognize tumor mucins. *Proc. AACR, vol. 83, abstract #1884, 1992.*
51. **Ioannides, C.G.** Antigens and vaccines in ovarian cancer. Williamsburg Conference on Immunity of Cancer, Biological and Immunological Treatments for Cancer, p. 27, 1992. *J. Immunother. 13:62, 1993.*
52. **Ioannides, C.G.**, Fisk, B., Ioannides, M.G., Freedman R.S., Flytzanes, C.N. and Finn, O.J. Antigens recognized by T cells in ovarian cancer. *4th International Meeting of Anticancer Research. October 1992. Anticancer Research, 12, 00, 1992.*
53. Fisk, B., Tucker, S.L., Pollack, M.S., Flytzanes, C.N., and **Ioannides, C.G.** Characterization of T-cell receptor Vb repertoire in ovarian tumor infiltrating lymphocytes. *Proc AACR 84, p. 459 (Abstract #2736), 1993.*
54. Fisk, B., Chessak, B. Pollack, M., Wharton, J.T., and **Ioannides, C.G.** Oligopeptide induction of a cytotoxic T cell response to HER-2/neu proto-oncogene in vitro. *Texas Immunology Conference, Galveston, 11/17-19/ 1993.*

55. Glisson, B., Fisk, B., Restifo, N., Agarwal, S., and **Ioannides, C.G.** Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon gamma (IFN g) in a multi-drug resistant (MDR) small cell lung cancer (SCLC) line. *Proc.AACR (A:2059, p. 346), 1994.*
56. Fisk, B., Chessak, B. Pollack, M., Wharton, J.T., and **Ioannides, C.G.** Oligopeptide induction of a cytotoxic T cell response to HER-2/neu proto-oncogene in vitro. *Proc.AACR, A:2967, p. 498, 1994.*
57. Blevins, T. L., Fisk, B., Wharton, J.T., Kavanagh, J.J., **Ioannides, C.G.**, and Kudelka, A.P. T Cell proliferating responses to HER-2 peptide analogs in ovarian cancer patients. *The FASEB J. 9(4): A800, 1995.*
58. Fisk, B., Blevins, T.L., Wharton, J.T., and **Ioannides, C.G.**, Identification of an immunodominant peptide of HER-2 recognized by ovarian tumor specific CTL. *The FASEB J. 9(4): A1023, 1995.*
59. Melichar, B., Hudson, J. M., Honda, T., Tuttle, T., Murray, J. L., Wharton, J. T., and **Ioannides, C. G.** Characterization of antigen recognition in tumor infiltrating lymphocytes in breast cancer. *The FASEB J. 10(5): A1470, 1996.*
60. **Ioannides, C. G.**, Fisk, B., Melichar, B., Anderson, B., Stifani, S., Papayannopoulos, I., Murray, J. L., Kudelka, A., and Wharton, J. T. Ovarian and breast cytotoxic lymphocytes can recognize peptides from the AES protein of the Notch complex. *The FASEB J. 10(5): A1437, 1996.*
61. Fisk, B., DaGue, B., Seifert, W. E., Lambris, J. D., Papayannopoulos, I., Kudelka, A., Wharton, J. T., and **Ioannides, C. G.** Ovarian cytotoxic T lymphocytes can recognize common peptides presented by HLA-A2+ tumors. *The FASEB J. 10(5): A1467, 1996.*
62. Murray, J. L., Hudson, M. J., Ross, M. I., and **Ioannides, C.G.** Defective TAP1 and TAP2 presentation of melanoma-specific peptide, MART-1. *Annual Conference on Clinical Immunology, 5/ 31 – 6/ 3, 1996, New Orleans, LA.*
63. **Ioannides, C. G.**, Murray, J. L., and Wharton, J. T. Recognition of breast and ovarian cancer antigens by T lymphocytes. *3rd International Conference: Engineered Vaccines for Cancer and AIDS, 10/ 9-14, 1996, Hilton Head Island, SC.*
64. Murray, J.L., Tuttle, T., Lee, J.E., Grabstein, K.H. and **Ioannides, C.G.** A novel HER2/neu peptide associated with Th1 responses in association with HLA-DR4 in breast cancer patients. *11th Annual Scientific Meeting, iSTBc 10/ 23- 26/ 1996, Washington, DC.*
65. Tuttle, T.M., Thompson, W.E., Anderson, B.W., Lee, J.E., Grabstein, K.W., Murray, J.L., Wharton, J.T., and **Ioannides, C.G.** A HER-2/neu peptide induces Th1 responses in association with HLA-DR4 in breast cancer patients. *J. Allergy and Clin. Immunol. 99(1), 546, 1997.*
66. Anderson, B.W., Swearingen II, B.J., Wharton, J.T., and **Ioannides, C.G.** Primary generation of human antitumor CTL by a HLA-A2 restricted HER-2 peptide. *Proc. AACR, Vol. 38, A1606, p239, 1997.*
67. Murray, J.L., Hudson, M., Anderson B.W., Castilleja, A., Singletary, E., Kudelka, A., Hortobagyi, G., and **Ioannides, C.G.** Growth and target recognition of tumor infiltrating lymphocytes from human breast cancer. *20th Annual San Antonio Breast Cancer Symposium. 12/ 3-6/1997, San Antonio, TX.*
68. **Ioannides, C.G.**, Hudson, M., Kudelka, A., Singletary, E., and Murray, J.L. Tumor antigen recognition by CTL associated breast tumors. *DOD Breast Cancer Meeting Era of Hope. 10/31-11/4/1997, Proc. Vol III, p. 983-994. Washington, DC.*
69. Peoples, G.E., Anderson, B.W., Eberlein, T.J., and **Ioannides, C.G.** Vaccine implications of a new cytotoxic T cell (CTL)-recognized antigen in epithelial cancers. *59th Annual Meeting Society of University Surgeons. 2/12-14, 1998, Milwaukee, WI.*
70. Peoples, G.E., Anderson, B.W., Kudelka, A., Murray, J.L., and **Ioannides, C.G.** Breast and ovarian cancer-associated lymphocytes recognize folate binding protein (FBP)-derived peptides: Vaccine implications. *59th Annual Meeting Society of University Surgeons. 2/ 12-14/1998, Milwaukee, WI.*
71. Anderson, B.W., Pollack, M.S., Kudelka, A.P. and **Ioannides, C.G.** Induction of determinant spreading in DR1101+ T cells using peptides corresponding to HER-2 helper epitopes results in a Th1 cytokine response. *Proc. AACR, 39:A572, p. 84, 1998.*
72. Murray, J.L., Babcock, B., Anderson, B., Kudelka, A., Wharton, J.T. and **Ioannides, C.G.** Ovarian and breast cytotoxic lymphocytes can recognize peptides from the AES protein of the Notch complex. *Proc. AACR,39; A1051, p 154, 1998.*
73. Castilleja, A., O'Brian, C.A., Anderson, B.W., Wharton, J.T. and **Ioannides, C.G.** Inhibition of CTL epitope presentation and tumor immunogenicity by HER-2 tyrosine phosphorylation. *The FASEB J. 12(4):A1684, p. 289, 1998.*
74. Peoples, G.E., Anderson, B.W., Kudelka, A.P., Eberlein, T.J., Wharton, J.T., **Ioannides, C.G.**, and Murray, J.L. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. *SBT 13th iSBTc Scientific Meeting, Plenary Lecture, Pittsburgh, PA, 10/1998.*
75. Anderson, B., Lu, J., Ibrahim, N., Hortobagyi, G., Brewer, H., Przepiorka, D., Ioannides, C., Grabstein, K., Cheever, M., and Murray, J. Immunomodulating effects of a HER2/neu derived HLA-A2 specific peptide E75 combined with GM-CSF in patients with metastatic breast and ovarian cancer. *Proc. ASCO, 18, A1691, 1999.*
76. Anderson, B. W., Peoples, G. E., Castilleja, A., Murray, J. L., Wharton, J. T., Bennink, J. R., Yewdell, J. W., and Ioannides, C. G. Rapid activation of CTL effector functions by HER-2 peptides reveals functionally distinct populations in healthy donors and breast cancer patients. *The FASEB J. 13, A481, 1999.*

77. Kim, D. K., Lee, T., Castilleja, A., Anderson, B. W., Peoples, G. E., Kudelka, A. J., Murray, J. L., Wharton, J. T., Kim, J. W. and Ioannides, C. G. Folate binding protein (FBP) peptides presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. *Proc. AACR*, 40, A4332, 1999.
78. Lee, T. V., Castilleja, A., Peoples, G. E., Kim, D. K., Gershenson, D. M., Ioannides, C. G. Secretion of CXC chemokine IP-10 by T cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. *17th Texas Immunology Conference, Galveston, 10/18/1999*.
79. Castilleja, A., Gillogly, M. A., Murray, J. L., Lee, T. V., Gershenson, D. M., and Ioannides, C. G. Potentiation of tumor immunity by variants of the antigen E75 (HER-2: 369-377). *17th Texas Immunology Conference, 10/18/1999*.

TEACHING

A. Formal teaching

1. M. D. Anderson Cancer Center, Department of Gynecologic Oncology (9/1989-9/1991 6/1999). Jan. 2000 and Jan. 2001. *Instructor, Special Courses: Immunology* (Course Director and Coordinator Dr. Ralph S. Freedman): (a). Lymphocyte surface antigens defined by monoclonal antibodies; (b). Differentiation of the lymphoid cells; (c). Organization and expression of immunoglobulins and T cell antigen receptor genes and surface molecules; (d). Research laboratory approaches for investigation of T and B lymphocytes functions; (e). Adoptive specific immunotherapy with tumor infiltrating lymphocytes; (f). Peptides; (g). vaccines.
2. *Lecturer, Human Immunotherapy Course (Course Director: Dr. G. Lopez-Berenstein), Spring 1999, Spring 2001, Spring 2002*
3. Graduate School of Biomedical Sciences, Graduate Program in Immunology (1992-Present), Houston, Texas.
4. Lecturer, Tumor Immunology Course, (Course Director: Dr. H. Ananthaswamy), Spring 1993, 1994, 1995. Lectures: Human tumor vaccines, human tumor antigens, Effector cells in human cancers.
5. Lecturer, Graduate School of Public Health, (Course Director: Dr. Margaret Kripke), Spring, 1993. Course on human tumor antigens and tumor vaccines.

A2. Training Programs

1. Immunology Program, M.D. Anderson, 9/89- 5/2008.
2. Cancer Biology Program, M.D. Anderson, 9/92-5/2003

A3. Supervisory teaching

a. Oral Examination Committee:

1. *Member*, Oral Examination Committee, Shankar Sellapan, 5/2003
2. *Chair*, Oral Examination Committee, Hui Gao, 11/2002
3. *Member*, Oral Examination Committee, Irving Pass, Ph.D. student, Fall 1999

b. Advisory Committees Member:

1. Thesis Advisory Committee, John Davis, 5/2005- 6/2006.(Graduated 2006).
2. Thesis Advisory Committee & Ombudsman Shankar Sellapan, 2002 – 2005 (Graduated May 2005)
3. Advisory Committee, and Thesis Advisory Committee Hui Gao, 2002 – 2005 (Graduated May 2005)
4. Advisory Committee, Xiaoyan Wang, 2000 – 2002.(Graduated 2004)
5. Thesis Advisory Committee, Bulent Ozpolat, M.D. 10/1995 -1998 (GSBS), (Graduated 2000).
6. Thesis Supervisory Committee, Floyd E. Fox, B.Sc. 9/1988-8/1990, (GSBS), graduated 1990.
7. Thesis Advisory Committee, George Mathioudakis, M.D. 4/1989-4/1990 (GSBS), graduated 1995.

c. Supervisory Committees:

1. Chairman, Thesis Supervisory Committee, Agapito Castilleja, B.Sc., 10/1997 – 1/2000. (GSBS)
2. Chairman, Thesis Supervisory Committee, Brett W. Anderson, B.Sc., 4/1997 – 8/1999. Graduated 1999.
3. Chairman, Thesis Supervisory Committee, Bryan Fisk, B.Sc. 1992-1994, (GSBS) Graduated 1994.

d. Students Directly Supervised:

1. YuFeng, Li, MSc, GSBS, 9/1-2005- 12/31/2005- tutorial, 1/1/2006-4/30/2006, 7/1-2007-collaboration see publications.
2. Satoko Matsueda, RN, Msc, GSBS- 11/12/2005- 4/30/2007. Foreign Advisor, Graduated 4/2007-Kurume, Japan.
3. Eric Swan, B.Sc., 8/2000 – 12/2000 (GSBS)
4. Tom V. Lee, B.Sc., 5/1999 – 5/2000 (GSBS) Graduated 2008.
5. Larry B. Anderson, M.D., Ph.D. Student, Spring, Summer, Fall, 1999, Summer 1995, (GSBS). Graduated, Spring, 2000.
6. Agapito Castilleja, B.Sc. 1/1997 – 1/2000 (GSBS), Defense Pending.
7. Brett W. Anderson, B.Sc., 8/ 1996 – 8/1999 (GSBS). Graduated 1999.

8. Bohuslav Melichar, M.D., 6/1995 – 2/1996, (GSBS)
9. Tracy Lynn Blevins, B.Sc., 5/1994 – 4/1995 (GSBS), Graduated Fall 1999.
10. Bryan Fisk B.Sc., 1991-1994, (GSBS). Graduated 1994
11. Sandeep Aggarwal, M.D., Ph.D. Student, Summer 1994, (GSBS). Graduated, Spring 2000.
12. Jonathan Trent, M.D., Ph.D., Student, Summer 1989, (GSBS). Graduated 1993.
13. George N. Reelos, Ph.D. 1983-1985, University of Athens, Greece. Graduated 1987.

e. Postgraduate Fellows Directly Supervised:

1. Satoshi Ishiyama, MD, 11/2005-12/2006. [Research for his PhD Thesis in U.Tokyo, Japan.](#)
2. Naotake Tsuda, MD, PhD., 6/2004 – 9/2006
3. Koichiro Kawano, M.D., Ph.D., 5/2002 – 6/2004.
4. Byung-Kyum Ko, M.D., Ph.D. Postdoctoral fellow, 3/2001-2/2002.
5. Moira Gillighan, Ph.D., University of Birmingham, England, 11/1995.
6. Toshie Honda, M.D., Ph.D. Visiting Assistant Professor, 9/1995 – 8/1996.
7. James Michael Hudson, Ph.D., Postdoctoral fellow, 1/1995 – 1/996.
8. Yong-Pil Kim, M.D., Ph.D., Postdoctoral fellow, (co-sponsor with Ralph S. Freedman), 1/1989 – 2/1990.

f. Clinical and Research Faculty Directly Supervised:

1. Takashi Mine, Visiting Assistant Professor, Kurume, Japan. 6/2006-6/2007.
2. David Z. Chang, MD, PhD, Assistant Professor, GI-Medical Oncology, 12/2004-9/2007.
3. Dong-Kyu Kim, M.D., Visiting Assistant Professor, Department of Gynecologic Oncology 4/1998 - 4/1999.
4. Henry Kuerer, MD, PhD, Assistant Professor, Surgical Oncology, 2000-2001.
5. George Vlastos, M.D., Visiting Fellow/Assistant Professor U.Geneva-Switzerland, Surgical Oncology, (9/1999 – 9/2000).
6. Nicholas Thomakos, M.D., Visiting Physician, Baylor College of Medicine (3/1998 – 2/1999)
7. Ira Braunschweig, M.D., Division of Medicine, M. D. Anderson Cancer Center. Spring 1997
8. Michael Chen, M.D. Department of Urology, Division of Surgery, M. D. Anderson Cancer Center, 9/1995 – 12/1996.
9. George E. Peoples, M.D, Junior Faculty Associate, Department of Surgical Oncology, 7/1997-6/1998.
10. Todd Tuttle, M.D. Junior Faculty Associate, Department of Surgical Oncology, 1/1996 – 6/1996.
11. Gabriela Baiocchi, M.D. Department of Gynecologic Oncology, 4/1988 – 6/1988 (Sponsors: Drs. Ralph S. Freedman and John Kavanagh).
12. Sabit Sinan Ozalp, M.D. Department of Gynecologic Oncology, 2/1991 – 3/1991 (Sponsor: Dr. Ralph S. Freedman).
13. Kung-Liahng Wang, M.D. Department of Gynecologic Oncology, 2/1991- 4/1991 (Sponsor: Dr. Ralph S. Freedman).

g. Medical and Undergraduate Students:

1. Sara Mouzi, 6-8/2001
2. Bruce Swearingen II, Medical Student, U. Guadalajara, México, 6-7/1997
3. Bryan Fisk, Medical Student, U.T. Houston Medical School, 6-8/1997
4. Mary Kaufmann, College Student, University of Houston, 1990
5. Michael Leung, College Student, Sponsor: Dr. Ralph S. Freedman, 6-8/1990
6. Sarah Fortune, College Student, University of Texas-Austin, 6-8/1989
7. Erin Swint, College Student, 6-8/1988

INVITATIONS AND PRESENTATIONS AT NATIONAL AND INTERNATIONAL CONFERENCES (2000 - 2010)

- 2010.** 1. BITs 1st Annual Word Congress in Immunodiseases and Therapy, Beijing May 2010.
2. 2nd International Conference in Drug Discovery and Therapy, Dubai , 2/2010.
- 2009.** 3. Invited Speaker: 7th Annual Congress of International Drug Discovery Science and Technology (IDDST). Theme: Milestones of Innovative Therapeutics, 10/ 22-25, 2009, Shanghai, China
4. **Invited Presenter.** 4th China Medical Biotech Forum. **Track 7: Monoclonal Antibodies and Vaccines** , 8/8-10, 2009, Dalian, China.
5. European Society of Immunology and Immunotherapy, Barcelona, Spain.
- 2008.** 6. **The Global Regulatory Summit**, Considerations in the Development of Oncology Biologics Products for the Treatment of Cancer" 10/29/2008 - San Diego, CA. Co-chairs: Raj Puri, MD - U.S.FDA , CBER & Ulrich Kalinke, PhD - Paul-Ehrlich-Institut, Germany.
7. The World Congress of Vaccine, December 6th -10th, 2008, Guangzhou, China.
8. The EHRlich II, 2nd World Conference on Magic Bullets, Oct 3-5, 2008 Nurenberg, Germany.
9. One more meeting in China, 2008.
10. Anticancer Research 2008.
11. International Journal of Oncology,
- 2006.** 12. Anticancer Research 2006.

13. Spandidos, Greece. 2006 (Invitation).
14. Anticancer Research, 2004. (Invitation).
15. Selected Symposium Presenter: Vaccine Development and Immune Based Therapies, Experimental Biology, 2005 San Diego 4/10/05. Abstract No. 26.
16. Selected Symposium Presenter, Society of Biological Therapy 17th Annual Meeting, San Diego, CA, 11/7/02. Abstract No. 11.
17. Selected Symposium Presenter: Vaccine Development and Immune Based Therapies, Experimental Biology, 2002, New Orleans, LA, 4/20/02. Abstract No. 9.
18. Selected Symposium Presenter: Antitumor effector cells and regulation of tumor immunity, Experimental Biology, 2002, New Orleans, LA, 4/20/02. Abstract No. 7.
20. Selected Symposium Presenter, Texas Immunology Conference 11/7/01, Oklahoma City, OK. (Abstract No. 5).
21. Selected Symposium Presenter, Experimental Biology 2001. Helper effects for HER-2 specific CTL induction by a HER-2 peptide. (Abstract No. 6) 3/31/2001, Orlando, FL.
22. Selected Symposium Presenter, Experimental Biology 2001. Induction of cancer immunity by targeted hydrophobic ladders in the tumor antigen. (Abstract No. 4) 4/02/2001, Orlando, FL.
23. Selected Symposium Presenter, Immunology 2000, April 12, 2000. Induction of immunity to HER-2 by TCR directed variants of the CTL Epitope E75, Seattle, WA. (Abstract No. 3).

Invitations to National and International Conferences (1995-1998)

24. Invited Speaker, Hellenic Immunological Society, Annual Meeting, Rapid activation of CTL effector functions by HER-2 peptides reveals functionally distinct populations in healthy individuals and breast cancer patients, Thessaloniki, Greece, 12/12/1998.
25. Invited Speaker, Functional Antigenics, NMHCC's International Conference on Therapeutic Development Based on Disease Specific Antigens, 11/20/1998, Washington, DC. Post-Translationally Enhanced Tumor Ag Immunogenicity.
26. Selected Symposium Presenter, FASEB 1998, San Francisco 4/19/98, Abstract #73, Inhibition of CTL epitope Presentation and tumor immunogenicity by HER-2 tyrosine phosphorylation.
27. Invited Speaker, Society for Biological Therapy, Annual Meeting, Abstract #64, Washington, DC 10/25/1996. A novel HER2/neu peptide associated with Th1 responses in association with HLA-DR4 in breast cancer patients.
28. Invited Speaker, Cambridge Symposia: 3rd International Conference on Engineered Vaccines for Cancer and AIDS, Abstract #63 Hilton Head, SC 10/10/1996. Recognition of breast and ovarian cancer antigens by T lymphocytes.
29. Selected Symposium Presenter, Annual Meeting of FASEB, New Orleans, Abstract #60, 6/1996. Ovarian and breast cytotoxic lymphocytes can recognize peptides from the AES protein of the Notch complex.

Invitations to National and International Conferences (1982-1995)

30. Selected Symposium Presenter, Annual Meeting of FASEB, Atlanta, Abstract #58, 4/1 1995. Identification of an immunodominant peptide of HER-2 recognized by ovarian tumor specific CTL.
31. Selected Symposium Presenter, Annual Meeting of AACR San Francisco, Abstract #56, 4/12/1994. Oligopeptide induction of cytotoxic T cell response to HER-2/neu proto-oncogene in vitro.
32. Invited Speaker, World Cancer Congress, New Delhi, India, (Host: Dr. Ronald Herberman) 8/1994.
33. Selected Symposium Presenter, Annual Meeting of the AACR, Orlando, Abstract #53, 5/1993. Characterization of T-cell receptor Vb repertoire in ovarian tumor infiltrating lymphocytes.
- 34.* Invited Speaker, Fourth International Forum on Ovarian Cancer, Toronto, (Book Chapter) 5/1993. Ovarian tumors reacting cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins.
- 35.* Invited Speaker, Williamsburg Conference on Immunity to Cancer, Abstract #51, 10/1992. Antigens and vaccines in ovarian cancer. Williamsburg Conference on Immunity of Cancer, Biological and Immunological Treatments for Cancer.
- 36.* Invited Speaker, 4th International Meeting of Anticancer Research, Abstract #52, 10/1992, Greece. Antigens recognized by T cells in ovarian cancer.
37. Selected Presenter, Annual Meeting of (AACR) Abstract #50, San Diego, 5/1992. Cytotoxic T cells isolated from ovarian tumor infiltrating lymphocytes can recognize tumor mucins.
38. Selected Presenter, Annual Meeting of FASEB, Anaheim, Abstract #49, 4/1992. CTL clones isolated from ovarian tumor infiltrating lymphocytes can recognize peptides with sequences corresponding to the HER2/Neu gene product.
39. Annual Meeting of AACR Houston, Texas, May 1991.
40. Annual Meeting of the Felix Rutledge Society, Houston, Texas, May, 1991.
41. Special Meeting of the FASEB, New Orleans, Louisiana, June, 1990.
42. Third International Scientific Meeting of Anticancer Research, 1990.
43. Sixteenth Meeting of the Federation of European Societies for Biological Sciences (FEBS), Moscow, USSR, 1984.
44. "Biotechnology Days 1984", Athens, Greece, 1984.
45. Special FEBS Meeting, Athens, Greece, 1982.
46. European Immunology Meeting, Istanbul, Turkey, 1982.

Seminar Invitations from Other Institutions (2000-present) (*)**

47. Mount Sinai School of Medicine, New York, (Host Dr. Adolfo Garcia-Sastre), Fall 2005.
48. University of Geneva, Switzerland, (Host Dr. George Vlastos), Summer 2002.

49. Karolinska University Sweden, (Host: Dr. Rolf Kiessling) Summer 2002.
50. Department of Biology, Prairie A&M University, 3/18/02 (Host: Ronald Humphrey, Ph.D.), Professor: Title: Immunotherapy of Cancer: Cancer Vaccines.
51. Tri-Services Grand Rounds, Department of Surgery, Walter Reed Army Medical Center (9-11/11/2000) (Hosts: Drs. George Peoples and Hans Schreiber) Title: Induction of Cancer Immunity by Targeted Hydrophobic Ladders in the Epitope. Tumor Ag as an immunomodulator.
52. Zonagen Corporation, The Woodlands Research Forrest, Houston, Texas. (Host: Mr. Mike Redman, CEO). (Title: Potentiation of tumor immunity by variants of tumor Ag E75 (HER-2:369-377), April 2, 2000.
- (***) Multiple seminar Invitations from Japan, China and Greece. Because I took care of my old mother who does not speak English, and my hearing is impaired, I sent my fellows to present.*

Seminar Invitations from Other Institutions (before 2000)

53. Wayne State University, Department of Microbiology and Immunology, Detroit, Michigan, (Title: T cell recognition of ovarian and breast tumors), 6/8/1999.
54. Mayo Clinic, Scottsdale, Arizona, (Host: Dr. John A. McDonald, Director of Research, 8/1998).
55. Argonex Corporation and University of Virginia, (Host: Dr. Kevin Hogan), 7/1998.
56. Walter Reed Army Institute for Research, Washington, D.C. (Host: Dr. George Tsokos), 11/3/97.
57. SmithKline Beechum, Brussels, Belgium, (Host: Dr. Claudine Bruick, Assoc. Director for Extramural Research), Summer 1997
58. St. Mary University, San Antonio, TX (Host: Dr. Jose Cimadevilla) 9/27/96
59. Systemix Corporation, Palo Alto, CA (Host: Dr. William G. Kerr) 8/11/95.
60. Fred Hutchinson Cancer Center, Seattle, Washington (Host: Dr. Martin Cheever) 2/24/1995.
61. Corixa Corporation, Seattle, Washington (Hosts: Dr. Kenneth Grabstein and Steve Gillis) 2/23/1995.
62. Cytel Corporation, San Diego, CA 4/30/1994 (Hosts: Dr. Esteban Celis and Howard M. Gray)
63. Arizona Cancer Center, Tucson, Arizona, 11/30/1993 (Hosts: Dr. John J. Marchalonis and Dr. Evan Hersh).
64. The Don and Sybil Harrington Cancer Center, Amarillo, Texas, September 1993 (Host: Dr. Phillip Periman)
65. Pittsburgh Cancer Institute, Pittsburgh, PA, February, 1993 (Host Dr. Theresa Whiteside).
66. Wayne State University, Detroit, January 1993 (Host Dr. Gunter Deppe).
67. University of Utrecht, Netherlands (Host: Professor Willem Den Otter, Chairman, Department of Experimental Pathology), September, 1991.
68. National Technical University, Athens, Greece (Host: Professor Dr. George Contaxis, Director, Electric Power Division and Professor, Dr. Constantin Ouzounoglou, Department Chairman), September, 1991.
69. National Research Foundation, Athens, Greece, 1990.
70. National Research Foundation, Athens, Greece, 1986.

PRESENTATIONS AT STATE AND LOCAL CONFERENCES, (2000-2010)

1. Technology Development Program: Host: Dr. Jim Klostergaard: Induction of tumor immunity by controlled modulation of the amino acid side chain length. 2/10/2002.
2. CDTP Symposium, Vaccine Immunotherapy: Host: Drs. L. Lachman and J. Klostergaard: Title: CTL induction to tumor Ag, 1/12/02.
3. Bioimmunotherapy Lecture Series: Topic: Cancer Immunity by Targeted Hydrophobic Ladders. (Host: Dr. B. Aggarwal) 10/24/00.
4. Human Immunotherapy Retreat – Vaccines, Topic: HER-2/neu vaccines, (Host: Dr. M. Talpaz) 5/23/98.
5. Endorex Corporation, Topic: Notch Peptides as Tumor Antigens, (Host: Dr. James L. Murray) 2/26/1997.
6. Cancer Therapeutics Discovery Initiative Retreat II (Host: Dr. Moshe Talpaz) 1/10/97.
7. Division of Laboratory Medicine (Host, Dr. Herbert Fritshe) 1/27/95
8. Department of Cell Biology, (Host, Dr. Eugenie Kleinerman,) 11/29/94.
9. Department of Breast and Gynecologic Medical Oncology (Host: Dr. John Kavanagh) 10/23/1994
10. Breast Cancer Research Group Retreat, Houston, Texas (Host: Dr. Gabriel Hortobagyi) 7/6/1994.
11. Clinical Immunology Seminar Series, 10/20/1993 (Host: Dr. Jordan Gutterman).
12. Biological Response Modifiers, 10/11/1993 (Host: Dr. Moshe Talpaz).
13. Smith Research Building Faculty Research Seminars, 1990.
14. Division of Surgery Research Seminars, M.D. Anderson 1990.
15. Division of Surgery Research Seminars, M.D. Anderson 1989.

Member in National and Local Societies

1. Public Relations, Publications, and Communications Committee of IBST 2007-2008.
2. American Association for Cancer Research, (1988), Chemistry in Cancer Research Working Group 2007 and Cancer Immunology Working Group 2007,
3. American Association of Immunologists, (1990)
4. International Society for Interferon Research, 1990
5. American Association for the Advancement of Science, 1986

- 6.M.D. Anderson Associates, 1987
 - 7.Texas Faculty Association, (2000-2007)
 - 11. American Chemical Society, 1988 – 1990
 - 12. American Federation for Clinical Research, 1990 - 1993
 - 13. New York Academy of Sciences, 1987 - 1990
 - 14. Hellenic Biophysical and Biochemical Society, 1981 -1986
 - 15. Hellenic Biological Society, 1981 - 1986
 - 16. Hellenic Chemical Society, 1978 – 1986
- REVIEWER OF LOCAL ,NATIONAL (USA) AND INTERNATIONAL (EU) PROGRAMS.

Education Committee, M.D. Anderson , 2003.
 ODYSSEY Fellowship Committee, M.D. Anderson 1999 - 2003.
 Clinical Protocols Review Committee, M.D. Anderson, 1997 - 2009

- 1. Austria- International,2009
- 2. Glaxo Oncology New Zealand – International,2008
- 3. Florida Department of Health, 2008. **National**
- 4. Poster Judge, Graduate School Poster Competition *March 23, 2007*.
- 5. Schissler Foundation.Fellowships of 16 (Sixteen) Grant Applications submitted to Graduate School,2006.
- 6. SOCRATES-ERASMUS EUROPEAN UNION Evaluator and External Advisor. 2005-2006-**International**
- 7. Federal Research Foundation of Republic of Austria, 2005-**International**
- 8. Italian Association for Cancer Research, Grant Review Committee, April 1988 – 2003.-**International**
- 9. NIH NIAID Special Emphasis Panel, Member, July 2003.-**National**
- 10. NCI Experimental Immunology Study Section, Member, June 2000.
- 11. California Breast Cancer Research Program, Innovative Treatments Study Section, Member, April 2000.
- 12..Arkansas Science and Technology Authority, National Panel Review Committee 2000-2010
- 13. Arizona Disease Control, Grant Review Committee, September 1997 – PRESENT
- 14. Israel Science Foundation, Grant Review Committee, Member, April 2000.
- 15. Summa Health Foundation, Grant Review Committee, August 1999.
- 16. Dutch Cancer Society, Grant Review Committee, June 1999.
- 17. American Cancer Society, Immunology and Immunotherapy. External Reviewer, 1994, 1996, 1997
- 18. NIH Special Reviewer, September 1993
- 19. Swiss National Science Foundation, Review Committee, 1993 –1996.
- 20. Study Section: NCI – RFA CA-92-18, 1992.
- 21. Lady Tata Memorial Trust, Review Committee (England), 1992.
- 22. BRSG Review Committee, M.D. Anderson, 1992.
- 23. (MBRSG) NIH and NCI, Review Committee, 1991.
- 24. Department of Science and Technology, Grant Review Committee (Greece), 1984 - 1985.

Journal Reviewer: **1.**The Journal of Immunology, 1990 – Present, **2.**The Journal of the National Cancer Institute, 1990 – Present, **3.**The Journal of Clinical Investigation, 1990 – 2000. **4.**Cancer Research, 1990 – Present, **5.**Clinical Cancer Research, 1996 – Present, **6.**International Journal of Cancer, 1990 – Present, **7.**Cancer Immunology Immunotherapy, 1990 – Present, **8.**Journal of Immunotherapy, 1990 – Present, **9.**Proceedings of the National Academy of Sciences, 1995 – 2000, **10.**Clinical Immunology Immunopathology, 1990 – 2000